| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2024 |
Bennett ME, Medoff D, Cowan T, Fang L, Kacmarek C, Oikonomou MT, Calkins ME, Baker KK, Bencivengo D, Boumaiz Y, Buchanan RW, Campbell P, Chengappa KNR, Conroy CG, Cooke A, ... ... Goldberg RW, et al. Tobacco smoking and nicotine vaping in persons with first episode psychosis. Schizophrenia Research. 267: 141-149. PMID 38547716 DOI: 10.1016/j.schres.2024.03.020 |
0.01 |
|
| 2024 |
Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, ... ... Goldberg RM, et al. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301326. PMID 38547438 DOI: 10.1200/JCO.23.01326 |
0.01 |
|
| 2024 |
Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F. Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301507. PMID 38457761 DOI: 10.1200/JCO.23.01507 |
0.01 |
|
| 2024 |
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, ... ... Goldberg RM, et al. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. European Journal of Cancer (Oxford, England : 1990). 201: 113914. PMID 38359495 DOI: 10.1016/j.ejca.2024.113914 |
0.01 |
|
| 2024 |
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, ... ... Goldberg RM, et al. and gene expression in colorectal cancer: comprehensive profiling and clinical value. Journal For Immunotherapy of Cancer. 12. PMID 38212126 DOI: 10.1136/jitc-2023-007939 |
0.01 |
|
| 2023 |
Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, Bassel ER, Xiu J, Farrell A, Lenz HJ, Lou E, Goel S, Spetzler D, Goldberg RM, Hazlehurst L. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Research Square. PMID 38234761 DOI: 10.21203/rs.3.rs-3787873/v1 |
0.01 |
|
| 2023 |
Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, LeBlanc M, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Goodman KA, Washington MK, Asare EA, Palis B. Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. Cancer. PMID 38140735 DOI: 10.1002/cncr.35155 |
0.01 |
|
| 2023 |
Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, Venook AP, Blanke CD, O'Reilly EM, Shields AF, et al. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance). Cancer. PMID 37651160 DOI: 10.1002/cncr.35007 |
0.01 |
|
| 2023 |
Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, et al. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers. 15. PMID 37627145 DOI: 10.3390/cancers15164117 |
0.01 |
|
| 2023 |
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, et al. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. International Journal of Cancer. PMID 37539667 DOI: 10.1002/ijc.34663 |
0.01 |
|
| 2023 |
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 3461-3468. PMID 37379691 DOI: 10.1200/JCO.22.02759 |
0.01 |
|
| 2023 |
Janczewski LM, Browner AE, Cotler JH, Nelson H, Kakar S, Carr NJ, Hanna NN, Holowatyj AN, Goldberg RM, Washington MK, Asare EA, Overman MJ. Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer. Ca: a Cancer Journal For Clinicians. PMID 37358310 DOI: 10.3322/caac.21806 |
0.01 |
|
| 2023 |
McGarrah P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control : Journal of the Moffitt Cancer Center. 30: 10732748231185047. PMID 37339926 DOI: 10.1177/10732748231185047 |
0.01 |
|
| 2023 |
Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, ... ... Goldberg RM, et al. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF10. PMID 37289007 DOI: 10.1158/1078-0432.CCR-23-0447 |
0.01 |
|
| 2023 |
Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, ... ... Goldberg RM, et al. Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37166477 DOI: 10.1158/1078-0432.CCR-23-0447 |
0.01 |
|
| 2023 |
Janczewski LM, Faski J, Nelson H, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Washington MK, Asare EA, Goodman KA. Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. Ca: a Cancer Journal For Clinicians. PMID 37114458 DOI: 10.3322/caac.21780 |
0.01 |
|
| 2023 |
Malla M, Fekrmandi F, Malik N, Hatoum H, George S, Goldberg RM, Mukherjee S. The evolving role of radiation in pancreatic cancer. Frontiers in Oncology. 12: 1060885. PMID 36713520 DOI: 10.3389/fonc.2022.1060885 |
0.01 |
|
| 2022 |
Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201637. PMID 36367997 DOI: 10.1200/JCO.22.01637 |
0.01 |
|
| 2022 |
Argilés G, Mulet N, Valladares-Ayerbes M, Viéitez JM, Grávalos C, García-Alfonso P, Santos C, Tobeña M, García-Paredes B, Benavides M, Cano MT, Loupakis F, Rodríguez-Garrote M, Rivera F, Goldberg RM, et al. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). European Journal of Cancer (Oxford, England : 1990). 177: 154-163. PMID 36335783 DOI: 10.1016/j.ejca.2022.09.037 |
0.01 |
|
| 2022 |
Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, et al. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102726. PMID 36306483 DOI: 10.1200/JCO.21.02726 |
0.01 |
|
| 2022 |
Malla M, Fuqua J, Mukherjee S, Goldberg RM. Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus. Current Treatment Options in Oncology. PMID 36272049 DOI: 10.1007/s11864-022-01029-0 |
0.01 |
|
| 2022 |
Peeples AD, Muralidharan A, McCarthy S, Goldberg R, Kuykendall L, Vineyard N, Chinman M. Barriers and Enablers to Implementing Peer Specialists in Veterans Health Administration Primary Care: a Qualitative Study. Journal of General Internal Medicine. PMID 36127539 DOI: 10.1007/s11606-022-07782-0 |
0.01 |
|
| 2022 |
Kocher F, Puccini A, Untergasser G, Martowicz A, Zimmer K, Pircher A, Baca Y, Xiu J, Haybaeck J, Tymoszuk P, Goldberg RM, Petrillo A, Shields AF, Salem ME, Marshall JL, et al. Multi-omic characterization of pancreatic ductal adenocarcinoma relates CXCR4 mRNA expression levels to potential clinical targets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36112544 DOI: 10.1158/1078-0432.CCR-22-0275 |
0.01 |
|
| 2022 |
Franko J, Yin J, Adams RA, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg RM, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, Yoshino T, de Gramont A, et al. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. European Journal of Cancer (Oxford, England : 1990). 174: 142-152. PMID 35994794 DOI: 10.1016/j.ejca.2022.07.021 |
0.01 |
|
| 2022 |
Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, et al. Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35984985 DOI: 10.1158/1055-9965.EPI-22-0320 |
0.01 |
|
| 2022 |
Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. Jco Precision Oncology. 6: e2200010. PMID 35952316 DOI: 10.1200/PO.22.00010 |
0.01 |
|
| 2022 |
Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405. International Journal of Cancer. PMID 35904874 DOI: 10.1002/ijc.34230 |
0.01 |
|
| 2022 |
Castellano AK, Powell JR, Cools MJ, Walton SR, Barnett RR, Delellis SM, Goldberg RL, Kane SF, Means GE, Zamora CA, Depenbrock PJ, Mihalik JP. Relationship between Anterior Pituitary Volume and IGF-1 Serum Levels in Soldiers with Mild Traumatic Brain Injury History. Medicine and Science in Sports and Exercise. 54: 1364-1370. PMID 35838301 DOI: 10.1249/MSS.0000000000002892 |
0.01 |
|
| 2022 |
Puccini A, Poorman K, Catalano F, Seeber A, Goldberg RM, Salem ME, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Philip PA, Marshall JL, Korn WM, et al. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene. PMID 35618879 DOI: 10.1038/s41388-022-02350-6 |
0.01 |
|
| 2022 |
McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, et al. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. Jnci Cancer Spectrum. 6. PMID 35603849 DOI: 10.1093/jncics/pkac014 |
0.01 |
|
| 2022 |
Heinlein E, Taylor J, Goldberg R, Potts W, RachBeisel J, Medoff D, Li L, Himelhoch S. Impact of a Targeted Intervention on Hepatitis C Care Among African Americans With Serious Mental Illness. Psychiatric Services (Washington, D.C.). appips202100410. PMID 35473365 DOI: 10.1176/appi.ps.202100410 |
0.01 |
|
| 2022 |
Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. European Journal of Cancer (Oxford, England : 1990). 166: 100-111. PMID 35279470 DOI: 10.1016/j.ejca.2022.02.005 |
0.01 |
|
| 2022 |
Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, et al. Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35254413 DOI: 10.1158/1078-0432.CCR-21-3018 |
0.01 |
|
| 2022 |
McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, et al. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. Journal of Geriatric Oncology. PMID 35105521 DOI: 10.1016/j.jgo.2022.01.006 |
0.01 |
|
| 2022 |
Goldberg R. Vaccine Liability in the Light of Covid-19: A Defence of Risk-Benefit. Medical Law Review. PMID 35026000 DOI: 10.1093/medlaw/fwab053 |
0.01 |
|
| 2021 |
Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, André T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, et al. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute. PMID 34865086 DOI: 10.1093/jnci/djab218 |
0.01 |
|
| 2021 |
Tonge NA, Travaglini LE, Brown CH, Muralidharan A, Goldberg RW. Impact of mental health on seeking pain care among veterans with serious mental illness. General Hospital Psychiatry. PMID 34839929 DOI: 10.1016/j.genhosppsych.2021.07.008 |
0.01 |
|
| 2021 |
Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, et al. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. PMID 34728807 DOI: 10.1038/s41388-021-02074-z |
0.01 |
|
| 2021 |
Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, et al. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics. PMID 34725190 DOI: 10.1158/1535-7163.MCT-20-0879 |
0.01 |
|
| 2021 |
Puccini A, Seeber A, Xiu J, Goldberg RM, Soldato D, Grothey A, Shields AF, Salem ME, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, et al. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology. 5: 95. PMID 34707195 DOI: 10.1038/s41698-021-00230-y |
0.01 |
|
| 2021 |
Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, ... ... Goldberg R, et al. Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute. PMID 34636852 DOI: 10.1093/jnci/djab200 |
0.01 |
|
| 2021 |
Masab M, Gross A, Flanagan M, Goldberg R, Malla M. Neuroendocrine Neoplasm of the Breast Presenting as a Liver Metastasis: A Rare Diagnostic Challenge. Cureus. 13: e16860. PMID 34513437 DOI: 10.7759/cureus.16860 |
0.01 |
|
| 2021 |
Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, De Gramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, et al. Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute. PMID 34505880 DOI: 10.1093/jnci/djab187 |
0.01 |
|
| 2021 |
Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shield AF, Jahagirdar BN, Jacobson SB, Foster NR, Pollak MN, Alberts SR. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. Jnci Cancer Spectrum. 5: pkab070. PMID 34485815 DOI: 10.1093/jncics/pkab070 |
0.01 |
|
| 2021 |
Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, ... ... Goldberg RM, et al. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute. PMID 34405233 DOI: 10.1093/jnci/djab123 |
0.01 |
|
| 2021 |
Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, et al. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology. 13: 17588359211020547. PMID 34262614 DOI: 10.1177/17588359211020547 |
0.01 |
|
| 2021 |
Pearlman R, Frankel WL, Swanson BJ, Jones D, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, et al. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. Jco Precision Oncology. 5. PMID 34250417 DOI: 10.1200/PO.20.00525 |
0.01 |
|
| 2021 |
Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, et al. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. PMID 34163031 DOI: 10.1038/s41388-021-01840-3 |
0.01 |
|
| 2021 |
Chinman M, Goldberg R, Daniels K, Muralidharan A, Smith J, McCarthy S, Medoff D, Peeples A, Kuykendall L, Vineyard N, Li L. Implementation of peer specialist services in VA primary care: a cluster randomized trial on the impact of external facilitation. Implementation Science : Is. 16: 60. PMID 34099004 DOI: 10.1186/s13012-021-01130-2 |
0.01 |
|
| 2021 |
Limburg PJ, Kisiel JB, Goldberg RM. In Memoriam, David A. Ahlquist, M.D. Gastroenterology. PMID 34087184 DOI: 10.1053/j.gastro.2021.06.001 |
0.01 |
|
| 2021 |
Hua X, Dai JY, Lindström S, Harrison TA, Lin Y, Alberts SR, Alwers E, Berndt SI, Brenner H, Buchanan DD, Campbell PT, Casey G, Chang-Claude J, Gallinger S, Giles GG, ... Goldberg RM, et al. Genetically predicted circulating C-reactive protein concentration and colorectal cancer survival: A Mendelian randomization consortium study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 33972368 DOI: 10.1158/1055-9965.EPI-20-1848 |
0.01 |
|
| 2021 |
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, ... ... Goldberg RM, et al. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. Jama. 325: 1277-1286. PMID 33821899 DOI: 10.1001/jama.2021.2454 |
0.01 |
|
| 2021 |
Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, et al. The landscape of alterations in DNA damage response pathways in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33766816 DOI: 10.1158/1078-0432.CCR-20-3635 |
0.01 |
|
| 2021 |
Holcombe RF, Verschraegen CF, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem M, Mims M, Mitchell EP, Mulkerin D, Vijayakumar S. Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 122-125. PMID 33545684 DOI: 10.6004/jnccn.2020.7685 |
0.01 |
|
| 2021 |
Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB, Atkins JN, ... Goldberg RM, et al. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. Jnci Cancer Spectrum. 5: pkaa074. PMID 33426464 DOI: 10.1093/jncics/pkaa074 |
0.01 |
|
| 2021 |
Kawanishi N, Baca Y, Xiu J, Arai H, Wang J, Battaglin F, Soni S, Zhang W, Shields AF, Goldberg RM, Weinberg BA, Lou E, Sohal D, Hall MJ, Seeber A, et al. Molecular characterization of pancreatic cancers as seen in the SLUG gene revealing cancer progression. Journal of Clinical Oncology. 39: 433-433. DOI: 10.1200/JCO.2021.39.3_SUPPL.433 |
0.01 |
|
| 2021 |
Jayachandran P, Xiu J, Soni S, Goldberg RM, Weinberg BA, Lou E, Hall MJ, Khushman MM, Sohal D, Battaglin F, Arai H, Zhang W, Wang J, Korn WM, Millstein J, et al. GDF15 expression in metastatic colorectal cancer. Journal of Clinical Oncology. 39: 116-116. DOI: 10.1200/JCO.2021.39.3_SUPPL.116 |
0.01 |
|
| 2021 |
Zimmer K, Kocher F, Untergasser G, Puccini A, Xiu J, Wolf D, Spizzo G, Goldberg RM, Grothey A, Shields AF, Marshall J, Hall MJ, Korn WM, Nabhan C, Battaglin F, et al. Identification and prognostic impact of PBRM1 mutations in biliary tract cancers: Results of a comprehensive molecular profiling study. Journal of Clinical Oncology. 39: 4022-4022. DOI: 10.1200/JCO.2021.39.15_SUPPL.4022 |
0.01 |
|
| 2021 |
Seeber A, Kocher F, Pircher A, Puccini A, Baca Y, Xiu J, Zimmer K, Haybaeck J, Spizzo G, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall J, Hall MJ, et al. High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach. Journal of Clinical Oncology. 39: 4021-4021. DOI: 10.1200/JCO.2021.39.15_SUPPL.4021 |
0.01 |
|
| 2021 |
Jin Z, Dixon JG, Parekh H, Sinicrope FA, Yothers G, Haller DG, Schmoll H, De Gramont A, Kerr R, Taieb J, Van Cutsem E, Twelves C, Saltz LB, Tomita N, Yoshino T, ... ... Goldberg RM, et al. Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database. Journal of Clinical Oncology. 39: 3597-3597. DOI: 10.1200/JCO.2021.39.15_SUPPL.3597 |
0.01 |
|
| 2021 |
Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shields AF, Jahagirdar BN, Jacobson SB, Foster NR, Pollak MN, Alberts SR. Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance). Journal of Clinical Oncology. 39: 3591-3591. DOI: 10.1200/JCO.2021.39.15_SUPPL.3591 |
0.01 |
|
| 2021 |
Van Blarigan E, Ma C, Ou F, Venook AP, Ng K, Niedzwiecki D, Giovannucci EL, Lenz H, Innocenti F, Shaw JE, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, O'Reilly EM, et al. Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance). Journal of Clinical Oncology. 39: 3588-3588. DOI: 10.1200/JCO.2021.39.15_SUPPL.3588 |
0.01 |
|
| 2021 |
Bachet J, Chibaudel B, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JRR, Mayer RJ, Lichtman SM, Benson A, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, et al. Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Journal of Clinical Oncology. 39: 3575-3575. DOI: 10.1200/JCO.2021.39.15_SUPPL.3575 |
0.01 |
|
| 2021 |
DiNardo K, Ma C, Ou F, Yuan C, Guercio BJ, Morales-Oyarvide V, Van Blarigan E, Niedzwiecki D, Chang I, Lenz H, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, ... ... Goldberg RM, et al. Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405. Journal of Clinical Oncology. 39: 3568-3568. DOI: 10.1200/JCO.2021.39.15_SUPPL.3568 |
0.01 |
|
| 2021 |
Lou E, Baca Y, Xiu J, Nelson A, Subramanian S, Salem ME, Beg MS, Fontana E, Diab M, Philip PA, Goldberg RM, Pandey R, Arkenau T, Sun W, Lenz H, et al. Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers. Journal of Clinical Oncology. 39: 3563-3563. DOI: 10.1200/JCO.2021.39.15_SUPPL.3563 |
0.01 |
|
| 2021 |
Battaglin F, Xiu J, Zeng J, Baca Y, Jayachandran P, Kawanishi N, Arai H, Deshpande K, Goldberg RM, Lockhart AC, Hwang JJ, Seeber A, Zhang W, Mumenthaler SM, Shields AF, et al. Comprehensive characterization of neurotransmitters and neuronal signaling (NT) pathway alterations in colorectal cancer (CRC). Journal of Clinical Oncology. 39: 3537-3537. DOI: 10.1200/JCO.2021.39.15_SUPPL.3537 |
0.01 |
|
| 2021 |
Jayachandran P, Baca Y, Xiu J, Zhang J, Battaglin F, Arai H, Goldberg RM, Weinberg BA, Lou E, Hall MJ, Khushman MM, Sohal D, Soni S, Wang J, Zhang W, et al. Globo H expression in metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 39: 3527-3527. DOI: 10.1200/JCO.2021.39.15_SUPPL.3527 |
0.01 |
|
| 2021 |
Puccini A, Xiu J, Heeke AL, Seeber A, Goldberg RM, El-Deiry WS, Liu SV, Sammons S, Lou E, Philip PA, Marshall J, Shields AF, Lenz H, Herzog TJ, Korn WM, et al. A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types. Journal of Clinical Oncology. 39: 3120-3120. DOI: 10.1200/JCO.2021.39.15_SUPPL.3120 |
0.01 |
|
| 2020 |
Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, et al. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001600. PMID 33356421 DOI: 10.1200/JCO.20.01600 |
0.01 |
|
| 2020 |
Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. European Journal of Cancer (Oxford, England : 1990). 144: 101-112. PMID 33341444 DOI: 10.1016/j.ejca.2020.11.016 |
0.01 |
|
| 2020 |
Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, et al. Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. Esmo Open. 5. PMID 33229504 DOI: 10.1136/esmoopen-2020-000942 |
0.01 |
|
| 2020 |
Labadie JD, Hua X, Harrison TA, Banbury BL, Huyghe JR, Sun W, Shi Q, Yothers G, Alberts SR, Sinicrope FA, Goldberg RM, George TJ, Penney KL, Phipps AI, Cohen SA, et al. Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 33203692 DOI: 10.1158/1055-9965.EPI-20-1274 |
0.01 |
|
| 2020 |
Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, et al. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. Jnci Cancer Spectrum. 4: pkaa024. PMID 33134818 DOI: 10.1093/jncics/pkaa024 |
0.01 |
|
| 2020 |
Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, ... ... Goldberg RM, et al. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. Jama Network Open. 3: e2023500. PMID 33125497 DOI: 10.1001/jamanetworkopen.2020.23500 |
0.01 |
|
| 2020 |
Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Naseem M, Puccini A, Berger MD, Soni S, Zhang W, Chen S, Hwang JJ, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European Journal of Cancer (Oxford, England : 1990). 140: 119-129. PMID 33080474 DOI: 10.1016/j.ejca.2020.09.006 |
0.01 |
|
| 2020 |
Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, et al. Molecular characterization of appendiceal goblet cell carcinoid. Molecular Cancer Therapeutics. PMID 33037134 DOI: 10.1158/1535-7163.MCT-20-0318 |
0.01 |
|
| 2020 |
Lopes GS, Tournigand C, Olswold CL, Cohen R, Kempf E, Saltz L, Goldberg RM, Hurwitz H, Fuchs C, de Gramont A, Shi Q. Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clinical Trials (London, England). 1740774520959313. PMID 32998522 DOI: 10.1177/1740774520959313 |
0.01 |
|
| 2020 |
Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, ... Goldberg RM, et al. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. Jama Oncology. PMID 32940631 DOI: 10.1001/jamaoncol.2020.3938 |
0.01 |
|
| 2020 |
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, et al. Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. Jco Precision Oncology. 4. PMID 32923882 DOI: 10.1200/PO.19.00237 |
0.01 |
|
| 2020 |
Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32883742 DOI: 10.1158/1078-0432.Ccr-20-1804 |
0.01 |
|
| 2020 |
Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, ... ... Goldberg RM, et al. Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. Journal of the National Cancer Institute. PMID 32835356 DOI: 10.1093/jnci/djaa124 |
0.01 |
|
| 2020 |
Muralidharan A, Peeples AD, Hack SM, Fortuna KL, Klingaman EA, Stahl NF, Phalen P, Lucksted A, Goldberg RW. Peer and Non-Peer Co-Facilitation of a Health and Wellness Intervention for Adults with Serious Mental Illness. The Psychiatric Quarterly. PMID 32794087 DOI: 10.1007/s11126-020-09818-2 |
0.01 |
|
| 2020 |
Liu Y, Lyu J, Bell Burdett K, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, et al. Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib. Molecular Cancer Therapeutics. PMID 32747417 DOI: 10.1158/1535-7163.Mct-20-0249 |
0.01 |
|
| 2020 |
Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, et al. Diagnosis of Digestive System Tumours. International Journal of Cancer. PMID 32674220 DOI: 10.1002/ijc.33210 |
0.01 |
|
| 2020 |
Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushmann M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, et al. Molecular profile of BRCA-mutated biliary tract cancers. Esmo Open. 5. PMID 32576609 DOI: 10.1136/esmoopen-2020-000682 |
0.01 |
|
| 2020 |
Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, et al. -Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers. 12. PMID 32455893 DOI: 10.3390/Cancers12051319 |
0.01 |
|
| 2020 |
Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. Jnci Cancer Spectrum. 4: pkaa023. PMID 32455336 DOI: 10.1093/Jncics/Pkaa023 |
0.01 |
|
| 2020 |
Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors. International Journal of Cancer. PMID 32449172 DOI: 10.1002/Ijc.33115 |
0.01 |
|
| 2020 |
Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, et al. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). Jnci Cancer Spectrum. 4: pkz078. PMID 32259016 DOI: 10.1093/jncics/pkz078 |
0.01 |
|
| 2020 |
Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, et al. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer (Oxford, England : 1990). 130: 63-71. PMID 32172199 DOI: 10.1016/j.ejca.2020.02.009 |
0.01 |
|
| 2020 |
Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, et al. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32085892 DOI: 10.1016/j.annonc.2019.12.007 |
0.01 |
|
| 2020 |
Goldberg RJ, Oxman TE. Billing for the Evaluation and Treatment of Adult Depression by the Primary Care Clinician. Primary Care Companion to the Journal of Clinical Psychiatry. 6: 21-26. PMID 15486597 DOI: 10.4088/pcc.v06n0105 |
0.01 |
|
| 2020 |
Tournigand C, Lopes G, Olswold CL, Adams R, Zalcberg JR, Van Cutsem E, Saltz LB, Goldberg RM, Hurwitz H, Bokemeyer C, Fuchs CS, Chibaudel B, Grothey A, De Gramont A, Shi Q. How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database. Journal of Clinical Oncology. 38: 89-89. DOI: 10.1200/jco.2020.38.4_suppl.89 |
0.01 |
|
| 2020 |
McCleary NJ, Harmsen WS, VanCutsem E, Sobrero AF, Goldberg RM, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Dirk A, Rothenberg ML, Koopman M, Schmoll Hh, Pitot HC, Hoff PM, et al. Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program. Journal of Clinical Oncology. 38: 6-6. DOI: 10.1200/jco.2020.38.4_suppl.6 |
0.01 |
|
| 2020 |
Battaglin F, Xiu J, Baca Y, Shields AF, Goldberg RM, Seeber A, Habib D, Soni S, Puccini A, Tokunaga R, Arai H, Wang J, Berger MD, Astsaturov IA, Lockhart AC, et al. Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC). Journal of Clinical Oncology. 38: 479-479. DOI: 10.1200/Jco.2020.38.4_Suppl.479 |
0.01 |
|
| 2020 |
Wang J, Xiu J, Baca Y, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Soni S, Tokunaga R, Zhang W, Hwang JJ, Shields AF, Marshall J, Astsaturov IA, et al. Molecular landscape of gastric cancer (GC) harboring mutations of histone methyltransferases. Journal of Clinical Oncology. 38: 418-418. DOI: 10.1200/Jco.2020.38.4_Suppl.418 |
0.01 |
|
| 2020 |
Malla M, Rozich N, Hassan A, Hayat M, Chen S, Nusrat S, Goldberg RM, Morris KT. Correlation of mesothelin (MSLN) expression with future peritoneal metastases (PM) in colorectal cancer (CRC). Journal of Clinical Oncology. 38: 176-176. DOI: 10.1200/jco.2020.38.4_suppl.176 |
0.01 |
|
| 2020 |
Malla M, Huebner LJ, Piawah S, Lenz H, Blanke CD, Meyerhardt JA, O'Reilly EM, Shi Q, Venook AP, Goldberg RM. Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively. Journal of Clinical Oncology. 38: e16076-e16076. DOI: 10.1200/jco.2020.38.15_suppl.e16076 |
0.01 |
|
| 2020 |
Arora S, Xiu J, Sohal D, Lou E, Goldberg RM, Weinberg BA, Grothey A, Korn WM, Khushman M, Shields AF, Marshall J, Hall MJ. The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB). Journal of Clinical Oncology. 38: e13538-e13538. DOI: 10.1200/Jco.2020.38.15_Suppl.E13538 |
0.01 |
|
| 2020 |
McCleary NJ, Harmsen WS, VanCutsem E, Sobrero AF, Goldberg RM, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Dirk A, Rothenberg ML, Koopman M, Schmoll H, Pitot HC, Hoff PM, et al. Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program. Journal of Clinical Oncology. 38: 7009-7009. DOI: 10.1200/jco.2020.38.15_suppl.7009 |
0.01 |
|
| 2020 |
Battaglin F, Xiu J, Baca Y, Zeng J, Shields AF, Goldberg RM, Seeber A, Habib D, Puccini A, Tokunaga R, Arai H, Wang J, Berger MD, Astsaturov IA, Lockhart AC, et al. Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC). Journal of Clinical Oncology. 38: 4598-4598. DOI: 10.1200/Jco.2020.38.15_Suppl.4598 |
0.01 |
|
| 2020 |
Stein MK, Elliott A, Hwang JJ, Lou E, Khushman MM, Scott AJ, Marshall J, Sohal D, Weinberg BA, Goldberg RM, Salem ME, Korn WM, Grothey A. The landscape of MAP3K1/MAP2K4 alterations in gastrointestinal (GI) malignancies. Journal of Clinical Oncology. 38: 4113-4113. DOI: 10.1200/jco.2020.38.15_suppl.4113 |
0.01 |
|
| 2020 |
Jin Z, Dixon JG, Parekh HD, Alberts SR, Yothers G, Allegra CJ, Kerr R, Haller DG, De Gramont A, Yoshino T, Van Cutsem E, Twelves C, Taieb J, Saltz LB, Seitz J, ... ... Goldberg RM, et al. Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. Journal of Clinical Oncology. 38: 4099-4099. DOI: 10.1200/jco.2020.38.15_suppl.4099 |
0.01 |
|
| 2020 |
Battaglin F, Ou F, Qu X, Bertagnolli MM, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz H, Innocenti F. Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 38: 4086-4086. DOI: 10.1200/jco.2020.38.15_suppl.4086 |
0.01 |
|
| 2020 |
Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, et al. Somatic alterations of NF1 in colorectal cancer. Journal of Clinical Oncology. 38: 4066-4066. DOI: 10.1200/Jco.2020.38.15_Suppl.4066 |
0.01 |
|
| 2020 |
Arai H, Elliott A, Wang J, Battaglin F, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall J, et al. The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4064-4064. DOI: 10.1200/jco.2020.38.15_suppl.4064 |
0.01 |
|
| 2020 |
Wagner AD, Rakez M, Chibaudel B, Adams R, Zalcberg JR, Saltz LB, Venook AP, Schmoll H, Douillard J, Tournigand C, Heinemann V, Goldberg RM, Hecht JR, Cremolini C, Diaz-Rubio E, et al. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. Journal of Clinical Oncology. 38: 4029-4029. DOI: 10.1200/jco.2020.38.15_suppl.4029 |
0.01 |
|
| 2020 |
Meyerhardt JA, Shi Q, Fuchs CS, Niedzwiecki D, Zemla TJ, Kumthekar P, Guthrie KA, Couture F, Kuebler JP, Bendell JC, Kumar P, Lewis DA, Tan BR, Bertagnolli MM, Grothey A, ... ... Goldberg RM, et al. Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702. Journal of Clinical Oncology. 38: 4003-4003. DOI: 10.1200/Jco.2020.38.15_Suppl.4003 |
0.01 |
|
| 2020 |
Battaglin F, Xiu J, Baca Y, Shields A, Goldberg R, Puccini A, Tokunaga R, Arai H, Wang J, Kawanishi N, Seeber A, Astaturov I, Lockhart A, Zhang W, Marshall J, et al. 1952P Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers Annals of Oncology. 31: S1100. DOI: 10.1016/j.annonc.2020.08.1344 |
0.01 |
|
| 2020 |
Salem M, Puccini A, Trufan S, Goldberg R, Worrilow W, Lenz H, Philip P, Grothey A, André T. SO-23 Prognostic impact of microsatellite instability/mismatch repair deficiency on patients with stage III colon cancer and stage IV colorectal cancers: Analysis of 42,984 patients in the National Cancer Database (NCDB) Annals of Oncology. 31: S225. DOI: 10.1016/j.annonc.2020.04.038 |
0.01 |
|
| 2019 |
Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. The Oncologist. PMID 31848314 DOI: 10.1634/Theoncologist.2019-0552 |
0.01 |
|
| 2019 |
Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, et al. Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31811950 DOI: 10.1016/J.Cgh.2019.11.046 |
0.01 |
|
| 2019 |
Young AS, Cohen AN, Niv N, Nowlin-Finch N, Oberman RS, Olmos-Ochoa TT, Goldberg RW, Whelan F. Mobile Phone and Smartphone Use by People With Serious Mental Illness. Psychiatric Services (Washington, D.C.). appips201900203. PMID 31744429 DOI: 10.1176/Appi.Ps.201900203 |
0.01 |
|
| 2019 |
Muralidharan A, Brown CH, Zhang Y, Niv N, Cohen AN, Kreyenbuhl J, Oberman RS, Goldberg RW, Young AS. Quality of life outcomes of web-based and in-person weight management for adults with serious mental illness. Journal of Behavioral Medicine. PMID 31741204 DOI: 10.1007/S10865-019-00117-1 |
0.01 |
|
| 2019 |
Travaglini LE, Kreyenbuhl J, Graydon M, Brown CH, Goldberg R, Himelhoch S, Fang LJ, Slade E. Access to Direct-Acting Antiviral Treatment for Hepatitis C Virus Among Veterans With Serious Mental Illness. Psychiatric Services (Washington, D.C.). appips201900227. PMID 31615365 DOI: 10.1176/Appi.Ps.201900227 |
0.01 |
|
| 2019 |
Yuan C, Sato K, Hollis BW, Zhang S, Niedzwieck D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, et al. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548349 DOI: 10.1158/1078-0432.CCR-19-0877 |
0.01 |
|
| 2019 |
Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, et al. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. Jama Network Open. 2: e1911750. PMID 31539075 DOI: 10.1001/jamanetworkopen.2019.11750 |
0.01 |
|
| 2019 |
Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, ... ... Goldberg RM, et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. Jama Oncology. PMID 31486832 DOI: 10.1001/jamaoncol.2019.2792 |
0.01 |
|
| 2019 |
Resnick SG, Goldberg RW. Psychiatric rehabilitation for veterans and the evolution of the field. Psychiatric Rehabilitation Journal. 42: 207-209. PMID 31464483 DOI: 10.1037/Prj0000383 |
0.01 |
|
| 2019 |
Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, et al. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901019. PMID 31408415 DOI: 10.1200/JCO.19.01019 |
0.01 |
|
| 2019 |
Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, et al. Reply to S. Sorscher. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901366. PMID 31268798 DOI: 10.1200/JCO.19.01366 |
0.01 |
|
| 2019 |
Phalen PL, Muralidharan A, Travaglini L, Bennett M, Stahl N, Brown C, Hack S, Klingaman EA, Goldberg R. Predictors of attendance in health and wellness treatment groups for people with serious mental illness. Psychiatric Rehabilitation Journal. PMID 31259581 DOI: 10.1037/Prj0000376 |
0.01 |
|
| 2019 |
Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, et al. Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. Journal of Geriatric Oncology. PMID 31201095 DOI: 10.1016/J.Jgo.2019.05.011 |
0.01 |
|
| 2019 |
El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca: a Cancer Journal For Clinicians. PMID 31116423 DOI: 10.3322/Caac.21560 |
0.01 |
|
| 2019 |
Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D levels and survival among patients with metastatic colorectal cancer. Cancer Causes & Control : Ccc. PMID 31104167 DOI: 10.1007/S10552-019-01183-1 |
0.01 |
|
| 2019 |
Olmos-Ochoa TT, Niv N, Hellemann G, Cohen AN, Oberman R, Goldberg R, Young AS. Barriers to participation in web-based and in-person weight management interventions for serious mental illness. Psychiatric Rehabilitation Journal. PMID 31081651 DOI: 10.1037/Prj0000363 |
0.01 |
|
| 2019 |
Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802258. PMID 31042420 DOI: 10.1200/JCO.18.02258 |
0.01 |
|
| 2019 |
Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801798. PMID 30865548 DOI: 10.1200/JCO.18.01798 |
0.01 |
|
| 2019 |
Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30692096 DOI: 10.1158/1078-0432.Ccr-18-3388 |
0.01 |
|
| 2019 |
Puccini A, Poorman K, Salem ME, Goldberg RM, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Soni S, Korn WM, Philip PA, Marshall J, Lenz H. Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon. Journal of Clinical Oncology. 37: 63-63. DOI: 10.1200/Jco.2019.37.4_Suppl.63 |
0.01 |
|
| 2019 |
Naseem M, Xiu J, Salem ME, Goldberg RM, Vanderwalde AM, Grothey A, Philip PA, Seeber A, Puccini A, Tokunaga R, Battaglin F, Berger MD, Barzi A, Hanna DL, Zhang W, et al. Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology. 37: 606-606. DOI: 10.1200/Jco.2019.37.4_Suppl.606 |
0.01 |
|
| 2019 |
Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Hwang JJ, Marshall J, Vanderwalde AM, Shields AF, Lenz H, Salem ME, Philip PA, Goldberg RM, Korn WM, Kim SS. Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers. Journal of Clinical Oncology. 37: 60-60. DOI: 10.1200/Jco.2019.37.4_Suppl.60 |
0.01 |
|
| 2019 |
Hall MJ, Bodor JN, Xiu J, Feldman R, Grothey A, Goldberg RM, Worrilow WM, Hwang JJ, Kim ES, Lenz H, Raghavan D, Shields AF, Marshall J, Korn WM, Salem ME. Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs). Journal of Clinical Oncology. 37: 505-505. DOI: 10.1200/Jco.2019.37.4_Suppl.505 |
0.01 |
|
| 2019 |
Jeter JM, Hampel H, Stanich P, Pearlman R, Hinton A, Hays JL, Goldberg RM. A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy. Journal of Clinical Oncology. 37: TPS1587-TPS1587. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS1587 |
0.01 |
|
| 2019 |
Seeber A, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Marshall J, Kocher F, Hall MJ, Korn WM, et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Journal of Clinical Oncology. 37: 4133-4133. DOI: 10.1200/Jco.2019.37.15_Suppl.4133 |
0.01 |
|
| 2019 |
Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman MM, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Hall MJ, Marshall J, et al. Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). Journal of Clinical Oncology. 37: 4085-4085. DOI: 10.1200/Jco.2019.37.15_Suppl.4085 |
0.01 |
|
| 2019 |
Stein MK, Xiu J, Martin MG, Grothey A, Prouet P, Owsley J, Williard FW, Glazer ES, Dickson PV, Shibata D, Yakoub D, Goldberg RM, Korn WM, Shields AF, Hwang JJ, et al. Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology. 37: 4053-4053. DOI: 10.1200/Jco.2019.37.15_Suppl.4053 |
0.01 |
|
| 2019 |
Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Puccini A, Naseem M, Berger MD, Soni S, Zhang W, Chen WS, Hwang JJ, et al. Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer. Journal of Clinical Oncology. 37: 3600-3600. DOI: 10.1200/Jco.2019.37.15_Suppl.3600 |
0.01 |
|
| 2019 |
Seeber A, Kocher F, Xiu J, Spizzo G, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Naseem M, et al. Molecular landscape of colorectal cancers harboring R-spondin fusions. Journal of Clinical Oncology. 37: 3588-3588. DOI: 10.1200/Jco.2019.37.15_Suppl.3588 |
0.01 |
|
| 2019 |
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julié C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, VAN Laethem JL, Le Malicot K, Sargent DJ, et al. Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials. Journal of Clinical Oncology. 37: 3583-3583. DOI: 10.1200/JCO.2019.37.15_SUPPL.3583 |
0.01 |
|
| 2019 |
Sinicrope FA, Huebner LJ, Laurent-Puig P, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Folprecht G, Zaanan A, Le Malicot K, Shi Q, Alberts SR, Taieb J. Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC). Journal of Clinical Oncology. 37: 3520-3520. DOI: 10.1200/JCO.2019.37.15_SUPPL.3520 |
0.01 |
|
| 2019 |
Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Seeber A, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, et al. Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC). Journal of Clinical Oncology. 37: 3130-3130. DOI: 10.1200/Jco.2019.37.15_Suppl.3130 |
0.01 |
|
| 2019 |
Guercio BJ, Venook AP, Zhang S, Ou F, Niedzwiecki D, Lenz H, Innocenti F, Pollak MN, Nixon AB, Mahoney MR, O'Neil B, Shaw JE, Polite BN, Denlinger CS, Atkins JN, ... Goldberg RM, et al. Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 37: 3035-3035. DOI: 10.1200/JCO.2019.37.15_SUPPL.3035 |
0.01 |
|
| 2019 |
Salem M, Xiu J, Puccini A, Grothey A, Goldberg R, Hwang J, Gatalica Z, Feldman R, Saul M, Korn W, Hall M, El-Deiry W, Shields A, Marshall J, Lenz H, et al. Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas Annals of Oncology. 30: v787. DOI: 10.1093/Annonc/Mdz268.084 |
0.01 |
|
| 2019 |
Battaglin F, Xiu J, Baca Y, Goldberg RM, Grothey A, Shields AF, Seeber A, Salem ME, Puccini A, Tokunaga R, Naseem M, Arai H, Wang J, Berger MD, Zhang W, et al. Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz268.009 |
0.01 |
|
| 2019 |
Seeber A, Puccini A, Xiu J, Baca Y, Spizzo G, Zimmer K, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, et al. WRN mutated colorectal cancer (CRC) is characterized by a distinct molecular and immunological profile Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz246.122 |
0.01 |
|
| 2018 |
Salem M, Grothey A, Goldberg R, Xiu J, Korn W, Shields A, Hwang J, Philip P, Lenz H, Marshall J. Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v109. PMID 32177004 DOI: 10.1093/Annonc/Mdy149.024 |
0.01 |
|
| 2018 |
Salem ME, Puccini A, Grothey A, Xiu J, Goldberg R, Kim ES, Korn WM, Lenz HJ, Raghavan D, Marshall JL, Hall MJ. Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii650-viii651. PMID 32137769 DOI: 10.1093/annonc/mdy303.005 |
0.01 |
|
| 2018 |
Puccini A, Poorman K, Goldberg R, Shields AF, Winerip M, Korn WM, Berger MD, Tokunaga R, Naseem M, Battaglin F, Zhang W, Soni S, Hwang JJ, Philip P, Marshall JL, et al. Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii649. PMID 32137763 DOI: 10.1093/Annonc/Mdy303.001 |
0.01 |
|
| 2018 |
Muralidharan A, Brown CH, E Peer J, A Klingaman E, M Hack S, Li L, Walsh MB, Goldberg RW. Living Well: An Intervention to Improve Medical Illness Self-Management Among Individuals With Serious Mental Illness. Psychiatric Services (Washington, D.C.). appips201800162. PMID 30353790 DOI: 10.1176/Appi.Ps.201800162 |
0.01 |
|
| 2018 |
Muralidharan A, Niv N, Brown CH, Olmos-Ochoa TT, Fang LJ, Cohen AN, Kreyenbuhl J, Oberman RS, Goldberg RW, Young AS. Impact of Online Weight Management With Peer Coaching on Physical Activity Levels of Adults With Serious Mental Illness. Psychiatric Services (Washington, D.C.). appips201700391. PMID 30041588 DOI: 10.1176/Appi.Ps.201700391 |
0.01 |
|
| 2018 |
Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. The Oncologist. PMID 30018131 DOI: 10.1634/Theoncologist.2018-0117 |
0.01 |
|
| 2018 |
Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. PMID 29905927 DOI: 10.1002/Cncr.31552 |
0.01 |
|
| 2018 |
Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. The Oncologist. PMID 29866946 DOI: 10.1634/Theoncologist.2018-0143 |
0.01 |
|
| 2018 |
Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. Esmo Open. 3: e000353. PMID 29765773 DOI: 10.1136/esmoopen-2018-000353 |
0.01 |
|
| 2018 |
Das S, Ciombor KK, Haraldsdottir S, Goldberg RM. Promising New Agents for Colorectal Cancer. Current Treatment Options in Oncology. 19: 29. PMID 29752549 DOI: 10.1007/s11864-018-0543-z |
0.01 |
|
| 2018 |
Peer JE, Gardner M, Autrey S, Calmes C, Goldberg RW. Feasibility of implementing a recovery education center in a Veterans Affairs medical center. Psychiatric Rehabilitation Journal. PMID 29708366 DOI: 10.1037/prj0000295 |
0.01 |
|
| 2018 |
Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, et al. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. Jama Oncology. PMID 29596542 DOI: 10.1001/Jamaoncol.2018.0104 |
0.01 |
|
| 2018 |
Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29563133 DOI: 10.1158/1055-9965.Epi-17-0769 |
0.01 |
|
| 2018 |
Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research : McR. PMID 29523759 DOI: 10.1158/1541-7786.Mcr-17-0735 |
0.01 |
|
| 2018 |
Ciombor KK, Goldberg RM. Hypermutated Tumors and Immune Checkpoint Inhibition. Drugs. PMID 29350327 DOI: 10.1007/s40265-018-0863-0 |
0.01 |
|
| 2018 |
Salem ME, Yin J, Goldberg RM, Pederson L, Wolmark N, Alberts SR, Taieb J, Marshall J, Lonardi S, Yoshino T, Kerr R, Yothers G, Grothey A, Andre T, De Gramont A, et al. Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database. Journal of Clinical Oncology. 36: 728-728. DOI: 10.1200/JCO.2018.36.4_suppl.728 |
0.01 |
|
| 2018 |
Salem ME, Yin J, Goldberg RM, Pederson L, Wolmark N, Alberts SR, Taieb J, Marshall J, Lonardi S, Yoshino T, Kerr R, Yothers G, Grothey A, Andre T, De Gramont A, et al. Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database. Journal of Clinical Oncology. 36: 724-724. DOI: 10.1200/JCO.2018.36.4_suppl.724 |
0.01 |
|
| 2018 |
Ferraro DA, Zalcberg JR, Shi Q, Meyers JP, Seymour MT, Saltz L, Maughan T, Goldberg RM, Van Cutsem E, Heinemann V, Hurwitz H, Falcone A, Diaz-Rubio E, Chibaudel B, Fuchs CS, et al. Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. Journal of Clinical Oncology. 36: 617-617. DOI: 10.1200/JCO.2018.36.4_SUPPL.617 |
0.01 |
|
| 2018 |
Sinicrope FA, Shi Q, Hermitte F, Heying EN, Benson AB, Gill S, Goldberg R, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Galon J, Alberts SR. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Journal of Clinical Oncology. 36: 614-614. DOI: 10.1200/Jco.2018.36.4_Suppl.614 |
0.01 |
|
| 2018 |
Ou F, Lou Y, Van Cutsem E, Saltz L, Schmoll H, Goldberg RM, Hoff P, Douillard J, Hecht JR, Hurwitz H, Punt CJA, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbut N, et al. Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. Journal of Clinical Oncology. 36: 612-612. DOI: 10.1200/JCO.2018.36.4_SUPPL.612 |
0.01 |
|
| 2018 |
Salem ME, Xiu J, Puccini A, Philip PA, Goldberg RM, Hwang JJ, Kc B, Korn WM, Shields AF, Lenz H, Marshall J. Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas. Journal of Clinical Oncology. 36: 60-60. DOI: 10.1200/Jco.2018.36.4_Suppl.60 |
0.01 |
|
| 2018 |
Puccini A, Poorman K, Salem ME, Goldberg RM, Shields AF, Xiu J, Korn WM, Seeber A, Berger MD, Tokunaga R, Naseem M, Battaglin F, Barzi A, Iqbal S, Zhang W, et al. Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Journal of Clinical Oncology. 36: 4098-4098. DOI: 10.1200/Jco.2018.36.15_Suppl.4098 |
0.01 |
|
| 2018 |
Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Puccini A, Naseem M, Battaglin F, Berger MD, Soni S, McSkane M, Barzi A, Zhang W, Hwang JJ, et al. Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC). Journal of Clinical Oncology. 36: 3611-3611. DOI: 10.1200/Jco.2018.36.15_Suppl.3611 |
0.01 |
|
| 2018 |
Wagner AD, Grothey A, Andre T, Dixon J, Wolmark N, Haller DG, Allegra CJ, VanCutsem E, George TJ, De Gramont A, Alberts SR, Twelves C, O'Connell M, Saltz LB, Blanke CD, ... ... Goldberg RM, et al. Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database. Journal of Clinical Oncology. 36: 3603-3603. DOI: 10.1200/JCO.2018.36.15_SUPPL.3603 |
0.01 |
|
| 2018 |
Cheung WY, Andre T, Grothey A, Kerr R, Dixon J, Haller DG, De Gramont A, Alberts SR, Twelves C, O'Connell MJ, Saltz LB, Lonardi S, Yoshino T, Yothers G, Goldberg RM, et al. Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database. Journal of Clinical Oncology. 36: 3601-3601. DOI: 10.1200/jco.2018.36.15_suppl.3601 |
0.01 |
|
| 2018 |
Penney K, Banbury BL, Shi Q, Allegra CJ, Alberts SR, Peters U, Yothers G, Sinicrope FA, Sun W, Nair S, Harrison TA, Goldberg RM, Lucas PC, Colangelo LH, Atkins JN, et al. Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology). Journal of Clinical Oncology. 36: 3582-3582. DOI: 10.1200/Jco.2018.36.15_Suppl.3582 |
0.01 |
|
| 2018 |
Jagosky M, Goldberg RM, Raghavan D, Puccini A, Shields AF, Arguello D, Korn WM, Seeber A, Hwang JJ, Philip PA, Marshall J, Kim ES, Lenz H, Salem ME. Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC). Journal of Clinical Oncology. 36: 3577-3577. DOI: 10.1200/Jco.2018.36.15_Suppl.3577 |
0.01 |
|
| 2018 |
Salem ME, Grothey A, Kim ES, Xiu J, Goldberg RM, Korn WM, Shields AF, Seeber A, Hwang JJ, Philip PA, Lenz H, Raghavan D, Marshall J. Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors. Journal of Clinical Oncology. 36: 3572-3572. DOI: 10.1200/Jco.2018.36.15_Suppl.3572 |
0.01 |
|
| 2018 |
Battaglin F, Xiu J, Winerip M, Goldberg RM, Philip PA, Seeber A, Puccini A, Tokunaga R, Naseem M, Soni S, McSkane M, Berger MD, Barzi A, Zhang W, Hwang JJ, et al. Circadian clock gene PER1 mutations in colorectal cancer (CRC). Journal of Clinical Oncology. 36: 12106-12106. DOI: 10.1200/Jco.2018.36.15_Suppl.12106 |
0.01 |
|
| 2017 |
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, et al. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute. PMID 29267900 DOI: 10.1093/jnci/djx253 |
0.01 |
|
| 2017 |
Goldberg RM, Wei L, Fernandez S. In Reply. The Oncologist. PMID 29133518 DOI: 10.1634/theoncologist.2017-0542 |
0.01 |
|
| 2017 |
Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, et al. Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. Oncotarget. 8: 75822-75833. PMID 29100271 DOI: 10.18632/Oncotarget.20616 |
0.01 |
|
| 2017 |
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, et al. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research. PMID 29038296 DOI: 10.1158/2326-6066.Cir-17-0375 |
0.01 |
|
| 2017 |
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, et al. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Jama Oncology. PMID 28983557 DOI: 10.1001/jamaoncol.2017.2899 |
0.01 |
|
| 2017 |
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, et al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017742130. PMID 28976791 DOI: 10.1200/JCO.2017.74.2130 |
0.01 |
|
| 2017 |
Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017739011. PMID 28817371 DOI: 10.1200/JCO.2017.73.9011 |
0.01 |
|
| 2017 |
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Jama. 317: 2392-2401. PMID 28632865 DOI: 10.1001/jama.2017.7105 |
0.01 |
|
| 2017 |
Goldberg RM, Wei L, Fernandez S. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs. The Oncologist. PMID 28620092 DOI: 10.1634/theoncologist.2017-0153 |
0.01 |
|
| 2017 |
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, ... ... Goldberg RM, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, N.Y.). PMID 28596308 DOI: 10.1126/Science.Aan6733 |
0.01 |
|
| 2017 |
Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, ... ... Goldberg RM, et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nature Communications. 8: 14755. PMID 28466842 DOI: 10.1038/Ncomms14755 |
0.01 |
|
| 2017 |
Chinman M, Daniels K, Smith J, McCarthy S, Medoff D, Peeples A, Goldberg R. Provision of peer specialist services in VA patient aligned care teams: protocol for testing a cluster randomized implementation trial. Implementation Science : Is. 12: 57. PMID 28464935 DOI: 10.1186/s13012-017-0587-7 |
0.01 |
|
| 2017 |
Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, et al. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28430862 DOI: 10.1093/annonc/mdx191 |
0.01 |
|
| 2017 |
Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, et al. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016715771. PMID 28414610 DOI: 10.1200/JCO.2016.71.5771 |
0.01 |
|
| 2017 |
Muralidharan A, Peeples AD, Lucksted A, Goldberg RW. Defining "peerness" in peer-delivered health and wellness interventions for serious mental illness. Psychiatric Rehabilitation Journal. 40: 116. PMID 28368186 DOI: 10.1037/prj0000249 |
0.01 |
|
| 2017 |
Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). Journal of Gastrointestinal Oncology. 8: 1-11. PMID 28280603 DOI: 10.21037/jgo.2016.12.13 |
0.01 |
|
| 2017 |
Young AS, Cohen AN, Goldberg R, Hellemann G, Kreyenbuhl J, Niv N, Nowlin-Finch N, Oberman R, Whelan F. Improving Weight in People with Serious Mental Illness: The Effectiveness of Computerized Services with Peer Coaches. Journal of General Internal Medicine. PMID 28271427 DOI: 10.1007/S11606-016-3963-0 |
0.01 |
|
| 2017 |
Muralidharan A, Klingaman EA, Molinari V, Goldberg RW. Perceived Barriers to Physical Activity in Older and Younger Veterans With Serious Mental Illness. Psychiatric Rehabilitation Journal. PMID 28125244 DOI: 10.1037/Prj0000245 |
0.01 |
|
| 2017 |
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, et al. Reply to L. Casadaban et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016712646. PMID 28113023 DOI: 10.1200/JCO.2016.71.2646 |
0.01 |
|
| 2017 |
Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Francois Emile J, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute. 109. PMID 28040692 DOI: 10.1093/jnci/djw272 |
0.01 |
|
| 2017 |
Guercio BJ, Venook AP, Niedzwiecki D, Zhang S, Sato K, Fuchs CS, Lenz H, Innocenti F, Fruth B, Van Blarigan E, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, ... Goldberg RM, et al. Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance). Journal of Clinical Oncology. 35: 659-659. DOI: 10.1200/JCO.2017.35.4_SUPPL.659 |
0.01 |
|
| 2017 |
Koenig KL, Wu CS, Chen W, Frankel WL, Jones D, Zhao W, Mikhail S, Roychowdhury S, Hays JL, Noonan AM, Goldberg RM, Bekaii-Saab TS, Ciombor KK. Genomic profiling of young adults with colorectal cancer: A single-institution experience. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E15168 |
0.01 |
|
| 2017 |
Newcomb PA, Sun W, Hua X, Banbury BL, Phipps AI, Kocarnik J, Harrison TA, Shi Q, Sinicrope FA, Thibodeau SN, Chan E, Gill S, Goldberg RM, Kahlenberg MS, Nair S, et al. Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance). Journal of Clinical Oncology. 35: 3604-3604. DOI: 10.1200/Jco.2017.35.15_Suppl.3604 |
0.01 |
|
| 2017 |
Zalcberg JR, Shi Q, Ferraro DA, Meyers JP, Saltz L, Goldberg R, Van Cutsem E, Hurwitz H, Fuchs C, Bokemeyer C, Sargent DJ, De Gramont A, Price TJ, Adams R. Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database. Journal of Clinical Oncology. 35: 3582-3582. DOI: 10.1200/JCO.2017.35.15_SUPPL.3582 |
0.01 |
|
| 2017 |
Sinicrope FA, Shi Q, Hermitte F, Heying EN, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Galon J, Alberts SR. Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). Journal of Clinical Oncology. 35: 3579-3579. DOI: 10.1200/Jco.2017.35.15_Suppl.3579 |
0.01 |
|
| 2017 |
Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Heying EN, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Jahagirdar BN, Pollak MN, Alberts SR. Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance). Journal of Clinical Oncology. 35: 3516-3516. DOI: 10.1200/Jco.2017.35.15_Suppl.3516 |
0.01 |
|
| 2017 |
Lenz H, Ou F, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Innocenti F, Kabbarah O. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 35: 3511-3511. DOI: 10.1200/JCO.2017.35.15_SUPPL.3511 |
0.01 |
|
| 2017 |
Innocenti F, Ou F, Zemla T, Niedzwiecki D, Qu X, Tam R, Mahajan S, Goldberg RM, Mayer RJ, Bertagnolli MM, Sanoff HK, Hochster HS, Blanke CD, Venook AP, Lenz H, et al. Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 35: 3504-3504. DOI: 10.1200/JCO.2017.35.15_SUPPL.3504 |
0.01 |
|
| 2017 |
Venook AP, Ou F, Lenz H, Kabbarah O, Qu X, Niedzwiecki D, Zemla T, Goldberg RM, Hochster HS, O'Neil BH, Sanoff HK, Mayer RJ, Bertagnolli MM, Blanke CD, Innocenti F. Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). Journal of Clinical Oncology. 35: 3503-3503. DOI: 10.1200/JCO.2017.35.15_SUPPL.3503 |
0.01 |
|
| 2017 |
Haraldsdottir S, Goldberg RM. Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy? Current Colorectal Cancer Reports. 13: 419-428. DOI: 10.1007/s11888-017-0393-2 |
0.01 |
|
| 2016 |
Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. Jama Oncology. PMID 28006055 DOI: 10.1001/jamaoncol.2016.5469 |
0.01 |
|
| 2016 |
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. Jama Oncology. PMID 27978560 DOI: 10.1001/Jamaoncol.2016.5194 |
0.01 |
|
| 2016 |
Goldberg RM. In Memoriam: A Tribute to Daniel J. Sargent, Ph.D. The Oncologist. 21: 1540-1541. PMID 27956661 DOI: 10.1634/theoncologist.2016-0425 |
0.01 |
|
| 2016 |
Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). The Oncologist. PMID 27881709 DOI: 10.1634/Theoncologist.2016-0153 |
0.01 |
|
| 2016 |
Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. The Oncologist. PMID 27821793 DOI: 10.1634/theoncologist.2016-0215 |
0.01 |
|
| 2016 |
Ciombor KK, Goldberg RM. Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable. Jama Oncology. PMID 27722749 DOI: 10.1001/jamaoncol.2016.3777 |
0.01 |
|
| 2016 |
Ciombor KK, Goldberg RM. Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy. Jama Oncology. PMID 27684887 DOI: 10.1001/jamaoncol.2016.3642 |
0.01 |
|
| 2016 |
Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Scientific Reports. 6: 33273. PMID 27623752 DOI: 10.1038/srep33273 |
0.01 |
|
| 2016 |
Muralidharan A, Klingaman EA, Prior SJ, Molinari V, Goldberg RW. Medical and Psychosocial Barriers to Weight Management in Older Veterans With and Without Serious Mental Illness. Psychological Services. PMID 27441416 DOI: 10.1037/Ser0000088 |
0.01 |
|
| 2016 |
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, et al. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27432924 DOI: 10.1200/JCO.2015.65.4699 |
0.01 |
|
| 2016 |
Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27382098 DOI: 10.1200/JCO.2015.65.5092 |
0.01 |
|
| 2016 |
Goodrich DE, Klingaman EA, Verchinina L, Goldberg RW, Littman AJ, Janney CA, Kim HM, Maguen S, Hoerster KD, Owen RR, Holleman RG, Roman P, Lai Z, Bowersox NW. Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program. Women's Health Issues : Official Publication of the Jacobs Institute of Women's Health. PMID 27365284 DOI: 10.1016/J.Whi.2016.05.001 |
0.01 |
|
| 2016 |
Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR. Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147. International Journal of Cancer. PMID 27060850 DOI: 10.1002/Ijc.30135 |
0.01 |
|
| 2016 |
Goldberg R. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer. Clinical Advances in Hematology & Oncology : H&O. 14: 30-3. PMID 27057664 |
0.01 |
|
| 2016 |
Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, Bekaii-Saab T. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26866578 DOI: 10.1038/Gim.2015.184 |
0.01 |
|
| 2016 |
Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncology (London, England). PMID 26777152 DOI: 10.2217/fon.15.327 |
0.01 |
|
| 2016 |
Klingaman EA, Hoerster KD, Aakre JM, Viverito KM, Medoff DR, Goldberg RW. Veterans with PTSD report more weight loss barriers than Veterans with no mental health disorders. General Hospital Psychiatry. 39: 1-7. PMID 26719103 DOI: 10.1016/J.Genhosppsych.2015.11.003 |
0.01 |
|
| 2016 |
Koenig KL, Burkart J, Mikhail S, Wu CS, Noonan AM, Goldberg RM, Bekaii-Saab TS, Ciombor KK. Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience. Journal of Clinical Oncology. 34: 584-584. DOI: 10.1200/JCO.2016.34.4_SUPPL.584 |
0.01 |
|
| 2016 |
Ahn DH, Ahn C, Jain A, Mikhail S, Wu CS, Goldberg RM, Ciombor KK, Noonan AM, Sadavartia P, Shroff RT, Javle MM, Chen JL, Bekaii-Saab TS. Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC). Journal of Clinical Oncology. 34: 287-287. DOI: 10.1200/jco.2016.34.4_suppl.287 |
0.01 |
|
| 2016 |
Bupathi M, Ahn DH, Ciombor KK, Wu CS, Mikhail S, Goldberg RM, Noonan AM, Stephens J, Reardon J, Hays JL, Bekaii-Saab TS. Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience. Journal of Clinical Oncology. 34: 215-215. DOI: 10.1200/JCO.2016.34.4_SUPPL.215 |
0.01 |
|
| 2016 |
Le DT, Uram JN, Wang H, Kemberling H, Eyring A, Bartlett B, Goldberg RM, Crocenzi TS, Fisher GA, Lee JJ, Greten TF, Laheru D, Azad NS, Donehower RC, Luber B, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Journal of Clinical Oncology. 34: 195-195. DOI: 10.1200/Jco.2016.34.4_Suppl.195 |
0.01 |
|
| 2016 |
Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, Siegel A, Balletti J, ... ... Goldberg RM, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). Journal of Clinical Oncology. 34: 192-192. DOI: 10.1200/JCO.2016.34.4_SUPPL.192 |
0.01 |
|
| 2016 |
Wu CS, Shi Q, Tomsic J, Meyers JP, Frankel WL, Timmers CD, Saltz L, Alberts SR, Niedzwiecki D, Sargent DJ, Hampel H, De La Chapelle A, Goldberg RM. Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147. Journal of Clinical Oncology. 34: e15148-e15148. DOI: 10.1200/JCO.2016.34.15_SUPPL.E15148 |
0.01 |
|
| 2016 |
Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Yothers G, Sargent DJ, Alberts SR. Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials. Journal of Clinical Oncology. 34: 3600-3600. DOI: 10.1200/JCO.2016.34.15_SUPPL.3600 |
0.01 |
|
| 2016 |
Sinicrope FA, Smyrk TC, Foster NR, Meyers JP, Thibodeau SN, Goldberg RM, Shi Q, Sargent DJ, Alberts SR. Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial. Journal of Clinical Oncology. 34: 3518-3518. DOI: 10.1200/JCO.2016.34.15_SUPPL.3518 |
0.01 |
|
| 2016 |
Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O'Reilly EM, Goldberg RM, Hochster HS, Blanke CD, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 34: 3504-3504. DOI: 10.1200/JCO.2016.34.15_SUPPL.3504 |
0.01 |
|
| 2016 |
Diaz LA, Uram JN, Wang H, Bartlett B, Kemberling H, Eyring A, Azad NS, Dauses T, Laheru D, Lee JJ, Crocenzi TS, Goldberg RM, Fisher GA, Greten TF, Meyer CF, et al. Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. Journal of Clinical Oncology. 34: 3003-3003. DOI: 10.1200/Jco.2016.34.15_Suppl.3003 |
0.01 |
|
| 2016 |
Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Bekaii-Saab TS, Hitchins MP, ... ... Goldberg RM, et al. Comprehensive population-wide detection of Lynch syndrome in Iceland. Journal of Clinical Oncology. 34: 1542-1542. DOI: 10.1200/JCO.2016.34.15_SUPPL.1542 |
0.01 |
|
| 2016 |
Le DT, Uram JN, Wang H, Bartlett B, Kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology. 34: 103-103. DOI: 10.1200/Jco.2016.34.15_Suppl.103 |
0.01 |
|
| 2016 |
Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X. Abstract 4919: Evaluating the gene expression of frozen tissue-derived prognostic signatures in FFPE colorectal cancer samples Cancer Research. 76: 4919-4919. DOI: 10.1158/1538-7445.Am2016-4919 |
0.01 |
|
| 2016 |
Wu C, Hampel H, Goldberg RM. PD-1 Inhibitor Shows Promising Results in Patients with MSI CRC Oncology Times. 38: 34-35. DOI: 10.1097/01.COT.0000482234.86460.35 |
0.01 |
|
| 2016 |
Grothey A, Falcone A, Humblet Y, Bouche O, Mineur L, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg R, Huang L, Wagner A, Van Cutsem E. Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial Annals of Oncology. 27: vi170. DOI: 10.1093/ANNONC/MDW370.64 |
0.01 |
|
| 2016 |
O'Neil B, O'Reilly S, Kasbari S, Kim R, McDermott R, Moore D, Grogan W, Cohn A, Bekaii-Saab T, Ivanova A, Olowokure O, Fernando N, McCaffrey J, El-Rayes B, Horgan A, ... ... Goldberg R, et al. A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy Annals of Oncology. 27: vi153. DOI: 10.1093/Annonc/Mdw370.13 |
0.01 |
|
| 2016 |
Henriques J, Vernerey D, de Gramont A, Chibaudel B, Van Cutsem E, Falcone A, Goldberg R, Shi Q, Bonnetain F, Shmueli E. O-012 Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis Annals of Oncology. 27: ii122. DOI: 10.1093/ANNONC/MDW198.12 |
0.01 |
|
| 2015 |
Ciombor KK, Goldberg RM. Update on Anti-Angiogenesis Therapy in Colorectal Cancer. Current Colorectal Cancer Reports. 11: 378-387. PMID 27551256 DOI: 10.1007/s11888-015-0292-3 |
0.01 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenetics and Genomics. PMID 26658227 DOI: 10.1097/Fpc.0000000000000197 |
0.01 |
|
| 2015 |
Dickerson F, Savage CL, Schweinfurth LA, Goldberg RW, Bennett M, Dixon L, Daumit G, Chinman M, Lucksted A. The Experience of Peer Mentors in an Intervention to Promote Smoking Cessation in Persons with Psychiatric Illness. Community Mental Health Journal. PMID 26602772 DOI: 10.1007/S10597-015-9967-0 |
0.01 |
|
| 2015 |
Goldberg R, Ringel MD. Ernest L. Mazzaferri, SR., MD 1936-2013. Transactions of the American Clinical and Climatological Association. 126: xcix-ci. PMID 26567406 |
0.01 |
|
| 2015 |
Goldberg RM. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? The Oncologist. 20: 1448-56. PMID 26512044 DOI: 10.1634/theoncologist.2015-0263 |
0.01 |
|
| 2015 |
Renfro LA, Loupakis F, Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, ... ... Goldberg RM, et al. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26503203 DOI: 10.1200/JCO.2015.61.6441 |
0.01 |
|
| 2015 |
Dickerson FB, Savage CL, Schweinfurth LA, Medoff DR, Goldberg RW, Bennett M, Lucksted A, Chinman M, Daumit G, Dixon L, DiClemente C. The Use of Peer Mentors to Enhance a Smoking Cessation Intervention for Persons With Serious Mental Illnesses. Psychiatric Rehabilitation Journal. PMID 26461436 DOI: 10.1037/Prj0000161 |
0.01 |
|
| 2015 |
Shaffer SL, Hutchison SL, Ayers AM, Goldberg RW, Herman D, Duch DA, Kogan JN, Terhorst L. Brief Critical Time Intervention to Reduce Psychiatric Rehospitalization. Psychiatric Services (Washington, D.C.). 66: 1155-61. PMID 26234327 DOI: 10.1176/appi.ps.201400362 |
0.01 |
|
| 2015 |
Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26187617 DOI: 10.1158/1078-0432.CCR-15-0527 |
0.01 |
|
| 2015 |
Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. The Lancet. Oncology. PMID 26184520 DOI: 10.1016/S1470-2045(15)00138-2 |
0.01 |
|
| 2015 |
Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. Journal of the National Cancer Institute. 107. PMID 26160882 DOI: 10.1093/jnci/djv186 |
0.01 |
|
| 2015 |
Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget. PMID 26082439 |
0.01 |
|
| 2015 |
Nordlinger BM, Poston GJ, Goldberg RM. Reply to J.N. Primrose et al and C.-H. Köhne. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2408-9. PMID 26033799 DOI: 10.1200/JCO.2014.60.4751 |
0.01 |
|
| 2015 |
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, ... ... Goldberg RM, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine. 372: 2509-20. PMID 26028255 DOI: 10.1200/Jco.2015.33.18_Suppl.Lba100 |
0.01 |
|
| 2015 |
Brown CH, Medoff D, Dickerson FB, Fang LJ, Lucksted A, Goldberg RW, Kreyenbuhl J, Himelhoch S, Dixon LB. Factors influencing implementation of smoking cessation treatment within community mental health centers. Journal of Dual Diagnosis. 11: 145-50. PMID 25985201 DOI: 10.1080/15504263.2015.1025025 |
0.01 |
|
| 2015 |
Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology. PMID 25723741 DOI: 10.1097/Coc.0000000000000185 |
0.01 |
|
| 2015 |
Bekaii-Saab T, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. Journal of the National Cancer Institute. 107. PMID 25638250 DOI: 10.1093/jnci/dju439 |
0.01 |
|
| 2015 |
Littman AJ, Damschroder LJ, Verchinina L, Lai Z, Kim HM, Hoerster KD, Klingaman EA, Goldberg RW, Owen RR, Goodrich DE. National evaluation of obesity screening and treatment among veterans with and without mental health disorders. General Hospital Psychiatry. 37: 7-13. PMID 25500194 DOI: 10.1016/J.Genhosppsych.2014.11.005 |
0.01 |
|
| 2015 |
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute. 107: 345. PMID 25432409 DOI: 10.1093/jnci/dju345 |
0.01 |
|
| 2015 |
Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). Journal of the National Cancer Institute. 107: 336. PMID 25432408 DOI: 10.1093/Jnci/Dju336 |
0.01 |
|
| 2015 |
Nordlinger B, Poston GJ, Goldberg RM. Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 241-3. PMID 25403221 DOI: 10.1200/JCO.2014.58.3989 |
0.01 |
|
| 2015 |
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 22-8. PMID 25385741 DOI: 10.1200/JCO.2014.56.5887 |
0.01 |
|
| 2015 |
Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of Surgical Oncology. 22: 1153-9. PMID 25358667 DOI: 10.1245/s10434-014-4225-1 |
0.01 |
|
| 2015 |
Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 36-41. PMID 25349295 DOI: 10.1200/JCO.2014.57.2826 |
0.01 |
|
| 2015 |
Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annual Review of Medicine. 66: 83-95. PMID 25341011 DOI: 10.1146/annurev-med-051513-102539 |
0.01 |
|
| 2015 |
Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 148: 88-99. PMID 25305506 DOI: 10.1053/J.Gastro.2014.09.041 |
0.01 |
|
| 2015 |
Grothey A, Falcone A, Humblet Y, Bouche O, Mineur L, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg RM, Xu L, Wagner A, Van Cutsem E. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. Journal of Clinical Oncology. 33: 710-710. DOI: 10.1200/jco.2015.33.3_suppl.710 |
0.01 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). Journal of Clinical Oncology. 33: 508-508. DOI: 10.1200/Jco.2015.33.3_Suppl.508 |
0.01 |
|
| 2015 |
Krishna K, Blazer MA, Wei L, Ahn DH, Wu CS, Ciombor KK, Mikhail S, Noonan AM, Goldberg RM, Bekaii-Saab TS. Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience. Journal of Clinical Oncology. 33: 366-366. DOI: 10.1200/JCO.2015.33.3_SUPPL.366 |
0.01 |
|
| 2015 |
Liu X, Adib DR, Barak H, Goldberg RM, Yazji S. Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3rd or 4th line treatment in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: TPS3633-TPS3633. DOI: 10.1200/JCO.2015.33.15_SUPPL.TPS3633 |
0.01 |
|
| 2015 |
Wilcox RE, Shi Q, Sinicrope FA, Sargent DJ, Foster NR, Meyers JP, Goldberg RM, Nair S, Shields AF, Chan E, Gill S, Kahlenberg MS, Alberts SR. Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). Journal of Clinical Oncology. 33: 3590-3590. DOI: 10.1200/Jco.2015.33.15_Suppl.3590 |
0.01 |
|
| 2015 |
Heinemann V, Niedzwiecki D, Pearline RV, Grothey A, Hochster HS, Goldberg RM, Innocenti F, Mayer RJ, Schilsky RL, Blanke CD, Bertagnolli MM, Venook AP, Stinzing S, O'Neil BH. Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. Journal of Clinical Oncology. 33: 3585-3585. DOI: 10.1200/JCO.2015.33.15_SUPPL.3585 |
0.01 |
|
| 2015 |
Singh PP, Shi Q, Foster NR, Grothey A, Nair S, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance). Journal of Clinical Oncology. 33: 3531-3531. DOI: 10.1200/Jco.2015.33.15_Suppl.3531 |
0.01 |
|
| 2015 |
Taieb J, Le Malicot K, Penault-Llorca FM, Bouche O, Shi Q, Thibodeau SN, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem J, Sargent DJ, Alberts SR, Laurent-Puig P, Sinicrope FA. Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. Journal of Clinical Oncology. 33: 3507-3507. DOI: 10.1200/JCO.2015.33.15_SUPPL.3507 |
0.01 |
|
| 2015 |
Zaanan A, Shi Q, Taieb J, Alberts SR, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, et al. Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. Journal of Clinical Oncology. 33: 3506-3506. DOI: 10.1200/JCO.2015.33.15_SUPPL.3506 |
0.01 |
|
| 2015 |
Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg MS, Nair S, Shields AF, Newcomb PA, Alberts SR. Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). Journal of Clinical Oncology. 33: 1508-1508. DOI: 10.1200/Jco.2015.33.15_Suppl.1508 |
0.01 |
|
| 2015 |
Sobrero A, Grothey A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg R, Xu L, et al. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months Annals of Oncology. 26: vi40. DOI: 10.1093/ANNONC/MDV340.13 |
0.01 |
|
| 2015 |
Zaanan A, Shi Q, Taieb J, Alberts S, Smyrk T, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg R, Folprecht G, Van Laethem J, Le Malicot K, Sargent D, Laurent Puig P, et al. O-021 Analysis of DNA mismatch repair and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials Annals of Oncology. 26: iv116. DOI: 10.1093/ANNONC/MDV235.20 |
0.01 |
|
| 2015 |
Taieb J, Le Malicot K, Penault-Llorca F, Bouche O, Shi Q, Thibodeau S, Tabernero J, Mini E, Zaanan Z, Goldberg R, Folprecht G, Van Laethem J, Sargent D, Alberts S, Laurent Puig P, et al. O-009 Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials Annals of Oncology. 26: iv110. DOI: 10.1093/ANNONC/MDV235.08 |
0.01 |
|
| 2015 |
Ciombor KK, Goldberg RM. Update on Anti-angiogenesis Therapy in Colorectal Cancer Current Colorectal Cancer Reports. 11: 378-387. DOI: 10.1007/s11888-015-0292-3 |
0.01 |
|
| 2014 |
Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepatic Oncology. 1: 331-345. PMID 30190967 DOI: 10.2217/hep.14.13 |
0.01 |
|
| 2014 |
Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA3. PMID 28141983 DOI: 10.1200/jco.2014.32.18_suppl.lba3 |
0.01 |
|
| 2014 |
Ciombor KK, Haraldsdottir S, Goldberg RM. How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? Current Colorectal Cancer Reports. 10: 372-379. PMID 25395895 DOI: 10.1007/s11888-014-0244-3 |
0.01 |
|
| 2014 |
Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). Journal of the National Cancer Institute. 106. PMID 25381393 DOI: 10.1093/jnci/dju298 |
0.01 |
|
| 2014 |
Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Maizels N. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. Plos One. 9: e108483. PMID 25310185 DOI: 10.1371/Journal.Pone.0108483 |
0.01 |
|
| 2014 |
Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston M. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 18: 2186-91. PMID 25300799 DOI: 10.1007/s11605-014-2670-6 |
0.01 |
|
| 2014 |
O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clinical Colorectal Cancer. 13: 156-163.e2. PMID 25066269 DOI: 10.1016/j.clcc.2014.04.001 |
0.01 |
|
| 2014 |
Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2975-84. PMID 25002720 DOI: 10.1200/JCO.2013.54.9329 |
0.01 |
|
| 2014 |
Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute. 106. PMID 24925349 DOI: 10.1093/jnci/dju106 |
0.01 |
|
| 2014 |
Klingaman EA, Viverito KM, Medoff DR, Hoffmann RM, Goldberg RW. Strategies, barriers, and motivation for weight loss among veterans living with schizophrenia. Psychiatric Rehabilitation Journal. 37: 270-6. PMID 24884299 DOI: 10.1037/prj0000084 |
0.01 |
|
| 2014 |
Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 147: 637-45. PMID 24859205 DOI: 10.1053/J.Gastro.2014.05.009 |
0.01 |
|
| 2014 |
McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 74: 117-23. PMID 24819684 DOI: 10.1007/S00280-014-2474-0 |
0.01 |
|
| 2014 |
Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. Plos One. 9: e94727. PMID 24727911 DOI: 10.1371/Journal.Pone.0094727 |
0.01 |
|
| 2014 |
Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3033-43. PMID 24687927 DOI: 10.1158/1078-0432.CCR-13-3140 |
0.01 |
|
| 2014 |
Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clinical Colorectal Cancer. 13: 100-9. PMID 24512953 DOI: 10.1016/J.Clcc.2013.12.002 |
0.01 |
|
| 2014 |
Albrecht JS, Gruber-Baldini AL, Hirshon JM, Brown CH, Goldberg R, Rosenberg JH, Comer AC, Furuno JP. Depressive symptoms and hospital readmission in older adults. Journal of the American Geriatrics Society. 62: 495-9. PMID 24512099 DOI: 10.1111/Jgs.12686 |
0.01 |
|
| 2014 |
Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 16: 553-7. PMID 24434690 DOI: 10.1038/gim.2013.193 |
0.01 |
|
| 2014 |
Marshall T, Goldberg RW, Braude L, Dougherty RH, Daniels AS, Ghose SS, George P, Delphin-Rittmon ME. Supported employment: assessing the evidence. Psychiatric Services (Washington, D.C.). 65: 16-23. PMID 24247197 DOI: 10.1176/appi.ps.201300262 |
0.01 |
|
| 2014 |
Murray M, Hardee A, Goldberg RL, Lewek MD. Loading and knee flexion after stroke: Less does not equal more. Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology. 24: 172-7. PMID 24210795 DOI: 10.1016/j.jelekin.2013.10.006 |
0.01 |
|
| 2014 |
Goldkamp W, Goldberg R, Patel K, Tombazzi C. Rare Case of GI Bleeding: Rectal Dieulafoy’s Lesion American Journal of Gastroenterology. 109: S414. DOI: 10.14309/00000434-201410002-01397 |
0.01 |
|
| 2014 |
Niedzwiecki D, Frankel W, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Kennedy RD, Davison T, O'Brien EJ, Mulligan J, Johnston PG, Harkin DP, Schilsky RL, et al. Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581. Journal of Clinical Oncology. 32: 455-455. DOI: 10.1200/JCO.2014.32.3_SUPPL.455 |
0.01 |
|
| 2014 |
Haraldsdottir S, Hampel H, Frankel W, Wu CS, Pan XJ, Bekaii-Saab TS, Goldberg RM. Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts). Journal of Clinical Oncology. 32: 419-419. DOI: 10.1200/jco.2014.32.3_suppl.419 |
0.01 |
|
| 2014 |
Haraldsdottir S, Wu CS, Hampel H, Frankel W, Pan XJ, Bekaii-Saab TS, Goldberg RM. Universal screening for Lynch syndrome (LS) in colorectal cancer (CRC) and survival. Journal of Clinical Oncology. 32: 415-415. DOI: 10.1200/JCO.2014.32.3_SUPPL.415 |
0.01 |
|
| 2014 |
Blazer MA, Wu CS, Goldberg RM, Phillips GS, Schmidt CR, Muscarella P, El-Dika SS, Walker JP, Krishna SG, Groce JR, Wuthrick EJ, Williams TM, Efries D, Smith YT, Mathey K, et al. Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). Journal of Clinical Oncology. 32: 275-275. DOI: 10.1200/Jco.2014.32.3_Suppl.275 |
0.01 |
|
| 2014 |
Sinicrope FA, Shi Q, Thibodeau SN, Goldberg RM, Sargent DJ, Alberts SR. Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Journal of Clinical Oncology. 32: 3512-3512. DOI: 10.1200/JCO.2014.32.15_SUPPL.3512 |
0.01 |
|
| 2014 |
Basu N, Johnson RA, Shi Q, Nelson GD, Cunningham JM, Goldberg RM, Sinicrope FA, Sargent DJ, Alberts SR, Petersen GM, Thibodeau SN, Skinner HG, Litzelman K, Seo S, Vanderboom RJ, et al. Abstract 5102: Telomeres and survival in stage III colon cancers: Findings from NCCTG N0147 (Alliance) study Cancer Research. 74: 5102-5102. DOI: 10.1158/1538-7445.Am2014-5102 |
0.01 |
|
| 2014 |
Venook A, Niedzwiecki D, Lenz H, Mahoney M, Innocenti F, O'Neil B, Hochster H, Goldberg R, Schilsky R, Mayer R, Polite B, Atkins J, Shaw J, Bertagnolli M, Blanke C. Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy Annals of Oncology. 25: v1. DOI: 10.1093/ANNONC/MDU438.8 |
0.01 |
|
| 2014 |
Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony M, O'Neil B, Shaw J, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Venook A. Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc) Annals of Oncology. 25: v1. DOI: 10.1093/ANNONC/MDU438.13 |
0.01 |
|
| 2014 |
Sinicrope F, Shi Q, Smyrk T, Goldberg R, Mahoney M, Sargent D, Alberts S. Molecular Subtype and Chemotherapy-Related Toxicity in Stage 3 Colon Cancers: Ncctg N0147 Annals of Oncology. 25: v1. DOI: 10.1093/ANNONC/MDU438.12 |
0.01 |
|
| 2014 |
Venook A, Niedzwiecki D, Lenz H, Innocenti F, Mahoney M, O'Neil B, Shaw J, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Blanke C. CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon Annals of Oncology. 25: ii112. DOI: 10.1093/ANNONC/MDU193.19 |
0.01 |
|
| 2013 |
Sanoff HK, Goldberg RM. How we treat metastatic colon cancer in older adults. Journal of Geriatric Oncology. 4: 295-301. PMID 24472471 DOI: 10.1016/j.jgo.2013.07.007 |
0.01 |
|
| 2013 |
Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. Journal of the National Cancer Institute. 105: 1789-98. PMID 24231454 DOI: 10.1093/Jnci/Djt298 |
0.01 |
|
| 2013 |
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and capecitabine Investigational New Drugs. 31: 1559-1567. PMID 24114122 DOI: 10.1007/S10637-013-0034-9 |
0.01 |
|
| 2013 |
Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 119: 4223-30. PMID 24105075 DOI: 10.1002/cncr.28358 |
0.01 |
|
| 2013 |
Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6957-66. PMID 24097873 DOI: 10.1158/1078-0432.CCR-13-0926 |
0.01 |
|
| 2013 |
Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3664-72. PMID 24019539 DOI: 10.1200/JCO.2013.48.9591 |
0.01 |
|
| 2013 |
Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5777-87. PMID 23983256 DOI: 10.1158/1078-0432.Ccr-13-0351 |
0.01 |
|
| 2013 |
Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Therapeutic Advances in Medical Oncology. 5: 221-34. PMID 23858331 DOI: 10.1177/1758834013485111 |
0.01 |
|
| 2013 |
Wu C, Goldberg RM. Managing choices for older patients with colon cancer: adjuvant therapy. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714498 DOI: 10.1200/EdBook_AM.2013.33.e190 |
0.01 |
|
| 2013 |
Bekaii-Saab T, Goldberg RM. FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future? The Oncologist. 18: 487-9. PMID 23704222 DOI: 10.1634/theoncologist.2013-0157 |
0.01 |
|
| 2013 |
Goldberg RW, Reeves G, Tapscott S, Medoff D, Dickerson F, Goldberg AP, Ryan AS, Fang LJ, Dixon LB. "MOVE!" Outcomes of a weight loss program modified for veterans with serious mental illness. Psychiatric Services (Washington, D.C.). 64: 737-44. PMID 23584716 DOI: 10.1176/appi.ps.201200314 |
0.01 |
|
| 2013 |
Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1775-81. PMID 23530100 DOI: 10.1200/JCO.2012.45.1096 |
0.01 |
|
| 2013 |
Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV, Oefinger M, Crum RM, Charleston J, Casagrande SS, Guallar E, ... Goldberg RW, et al. A behavioral weight-loss intervention in persons with serious mental illness. The New England Journal of Medicine. 368: 1594-602. PMID 23517118 DOI: 10.1056/Nejmoa1214530 |
0.01 |
|
| 2013 |
Slade EP, Rosenberg S, Dixon LB, Goldberg RW, Wolford GL, Himelhoch S, Tapscott S. Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness. Psychiatric Services (Washington, D.C.). 64: 127-33. PMID 23475451 DOI: 10.1176/appi.ps.000852011 |
0.01 |
|
| 2013 |
Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer. 12: 95-102. PMID 23317558 DOI: 10.1016/j.clcc.2012.11.002 |
0.01 |
|
| 2013 |
Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 119: 1528-36. PMID 23310947 DOI: 10.1002/cncr.27938 |
0.01 |
|
| 2013 |
Wu C, Goldberg RM. Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies. Nature Reviews. Clinical Oncology. 10: 71-2. PMID 23296108 DOI: 10.1038/nrclinonc.2012.227 |
0.01 |
|
| 2013 |
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 381: 303-12. PMID 23177514 DOI: 10.1016/S0140-6736(12)61900-X |
0.01 |
|
| 2013 |
Goldberg RW, Dickerson F, Lucksted A, Brown CH, Weber E, Tenhula WN, Kreyenbuhl J, Dixon LB. Living well: an intervention to improve self-management of medical illness for individuals with serious mental illness. Psychiatric Services (Washington, D.C.). 64: 51-7. PMID 23070062 DOI: 10.1176/Appi.Ps.201200034 |
0.01 |
|
| 2013 |
Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. American Journal of Clinical Oncology. 36: 250-3. PMID 22547007 DOI: 10.1097/Coc.0B013E3182467F22 |
0.01 |
|
| 2013 |
Sheikh I, Yahya F, Goldberg R, Ismail M. Iron Deficiency Anemia: The Inexorable Complication of Bariatric Surgery American Journal of Gastroenterology. 108: S314. DOI: 10.14309/00000434-201310001-01052 |
0.01 |
|
| 2013 |
Wu CS, Wei L, Glass K, Wilson J, Abdel-Misih S, Martin LK, Haraldsdottir S, Harzman A, Husain S, Schmidt CR, Arnold M, Goldberg RM, Bekaii-Saab TS. Survival differences in patients (pts) with resected rectal cancer who received neoadjuvant therapy with or without postoperative chemotherapy (CT). Journal of Clinical Oncology. 31: 518-518. DOI: 10.1200/JCO.2013.31.4_SUPPL.518 |
0.01 |
|
| 2013 |
Grothey A, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg RM, et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study. Journal of Clinical Oncology. 31: 467-467. DOI: 10.1200/JCO.2013.31.4_SUPPL.467 |
0.01 |
|
| 2013 |
Jeffers M, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg RM, et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. Journal of Clinical Oncology. 31: 381-381. DOI: 10.1200/JCO.2013.31.4_SUPPL.381 |
0.01 |
|
| 2013 |
Wu CS, Wei L, Glass K, Wilson J, Abdel-Misih S, Williams TM, Martin LK, Haraldsdottir S, Harzman A, Husain S, Schmidt CR, Arnold M, Goldberg RM, Bekaii-Saab TB. Effect of postoperative chemotherapy (CT) on survival in patients (pts) with resected rectal cancer who received neoadjuvant therapy. Journal of Clinical Oncology. 31: e14535-e14535. DOI: 10.1200/Jco.2013.31.15_Suppl.E14535 |
0.01 |
|
| 2013 |
Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Argiles G, Yoshino T, Lenz H, Goldberg RM, Sargent DJ, et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. Journal of Clinical Oncology. 31: 3637-3637. DOI: 10.1200/JCO.2013.31.15_SUPPL.3637 |
0.01 |
|
| 2013 |
van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Argilés G, Yoshino T, Lenz H, Goldberg RM, Sargent DJ, et al. Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. Journal of Clinical Oncology. 31: 3636-3636. DOI: 10.1200/JCO.2013.31.15_SUPPL.3636 |
0.01 |
|
| 2013 |
Lenz H, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Goldberg RM, Sargent DJ, et al. Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. Journal of Clinical Oncology. 31: 3514-3514. DOI: 10.1200/JCO.2013.31.15_SUPPL.3514 |
0.01 |
|
| 2013 |
Lee A, Shi Q, Pavey ES, Sargent DJ, Alberts SR, Sinicrope FA, Berenberg J, Goldberg RM, Diasio RB. Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. Journal of Clinical Oncology. 31: 3510-3510. DOI: 10.1200/Jco.2013.31.15_Suppl.3510 |
0.01 |
|
| 2013 |
Patel JN, Deal AM, O'Neil BH, Ibrahim J, Sherrill GB, Davies JM, Bernard SA, Goldberg RM, Olajide OA, Atluri P, Inzerillo JJ, McLeod HL, Walko CM. Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice. Journal of Clinical Oncology. 31: 2595-2595. DOI: 10.1200/Jco.2013.31.15_Suppl.2595 |
0.01 |
|
| 2013 |
Haraldsdottir S, Wu CS, Pan XJ, Hampel H, Goldberg RM, Bekaii-Saab TS. Differences in outcome between colorectal cancer (CRC) patients (pts) with Lynch syndrome (LS) versus MLH1 hypermethylation (MLH1 HM). Journal of Clinical Oncology. 31: 1556-1556. DOI: 10.1200/JCO.2013.31.15_SUPPL.1556 |
0.01 |
|
| 2013 |
Stein A, Jeffers M, van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, ... Goldberg R, et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib Zeitschrift FüR Gastroenterologie. 51. DOI: 10.1055/S-0033-1352702 |
0.01 |
|
| 2013 |
Denzlinger C, Grothey A, Sobrero A, van Cutsem E, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, ... Goldberg R, et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study Zeitschrift FüR Gastroenterologie. 51. DOI: 10.1055/s-0033-1352701 |
0.01 |
|
| 2013 |
Little B, Heard R, Swift CN, Fontenot E, Goldberg R, Chaudhry S. Sa1181 Role of Positive Technetium 99m-Labeled Red Blood Cell Scintigraphy in Brisk Gastrointestinal Bleeding to Predict Advanced Management and Correct Bleeding Site Identification Gastroenterology. 144: S-222. DOI: 10.1016/S0016-5085(13)60787-8 |
0.01 |
|
| 2013 |
Wu C, Goldberg RM. The role of adjuvant therapy in the elderly Current Colorectal Cancer Reports. 9: 286-291. DOI: 10.1007/s11888-013-0175-4 |
0.01 |
|
| 2012 |
Atreya CE, Warren RS, Niedzwiecki D, Mayer RJ, Goldberg RM, Compton CC, Zuraek M, Bergsland EK, Ye C, Weinberg VK, Bertagnolli MM. A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 452. PMID 27983199 DOI: 10.1200/jco.2012.30.4_suppl.452 |
0.01 |
|
| 2012 |
Goldberg RM, Garrett CR, Berkowitz NC, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shmueli E, Buchbinder A. Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 448. PMID 27983143 DOI: 10.1200/jco.2012.30.4_suppl.448 |
0.01 |
|
| 2012 |
Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, Lee PH, Gramont A, Rothenberg ML, André T, Brienza S, Goldberg RM. Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Cancer Medicine. 1: 198-206. PMID 23342269 DOI: 10.1002/cam4.25 |
0.01 |
|
| 2012 |
Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2624-34. PMID 22665536 DOI: 10.1200/Jco.2011.41.1140 |
0.01 |
|
| 2012 |
Albrecht JS, Hirshon JM, Goldberg R, Langenberg P, Day HR, Morgan DJ, Comer AC, Harris AD, Furuno JP. Serious mental illness and acute hospital readmission in diabetic patients. American Journal of Medical Quality : the Official Journal of the American College of Medical Quality. 27: 503-8. PMID 22539798 DOI: 10.1177/1062860612436576 |
0.01 |
|
| 2012 |
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, ... ... Goldberg RM, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. Jama. 307: 1383-93. PMID 22474202 DOI: 10.1001/Jama.2012.385 |
0.01 |
|
| 2012 |
Carpenter WR, Meyer AM, Wu Y, Qaqish B, Sanoff HK, Goldberg RM, Weiner BJ. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Medical Care. 50: 737-48. PMID 22437624 DOI: 10.1097/Mlr.0B013E31824Ebe13 |
0.01 |
|
| 2012 |
Welsh C, Goldberg R, Tapscott S, Medoff D, Rosenberg S, Dixon L. "Shotgunning" in a population of patients with severe mental illness and comorbid substance use disorders. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 21: 120-5. PMID 22332854 DOI: 10.1111/j.1521-0391.2011.00201.x |
0.01 |
|
| 2012 |
Sargent DJ, Buyse M, Matheson A, Goldberg RM, de Gramont A. The ARCAD clinical trials program: an update and invitation. The Oncologist. 17: 188-91. PMID 22302228 DOI: 10.1634/theoncologist.2011-0332 |
0.01 |
|
| 2012 |
Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 118: 4309-20. PMID 22294436 DOI: 10.1002/cncr.27422 |
0.01 |
|
| 2012 |
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 263-7. PMID 22162570 DOI: 10.1200/Jco.2011.37.1039 |
0.01 |
|
| 2012 |
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 890-900. PMID 22147942 DOI: 10.1158/1078-0432.Ccr-11-2246 |
0.01 |
|
| 2012 |
Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, ... ... Goldberg RM, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 577-84. PMID 22142827 DOI: 10.1158/1078-0432.Ccr-11-1387 |
0.01 |
|
| 2012 |
Buyse M, Sargent DJ, Goldberg RM, de gramont A. The ARCAD advanced colorectal cancer database-open for business Annals of Oncology. 23: 281-282. PMID 22104572 DOI: 10.1093/annonc/mdr547 |
0.01 |
|
| 2012 |
Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee PH, de Gramont A, Goldberg RM, Rothenberg ML, André T, Brienza S, Gomi K. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clinical Colorectal Cancer. 11: 127-37. PMID 22099928 DOI: 10.1016/j.clcc.2011.09.001 |
0.01 |
|
| 2012 |
Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. International Journal of Cancer. Journal International Du Cancer. 131: 438-45. PMID 21898389 DOI: 10.1002/ijc.26400 |
0.01 |
|
| 2012 |
Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 118: 571-8. PMID 21713765 DOI: 10.1002/Cncr.26270 |
0.01 |
|
| 2012 |
Haraldsdottir S, Rose JS, Wu C, Wei L, Goldberg RM, Bekaii-Saab T. A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer Journal of Cancer Therapy. 3: 948-955. DOI: 10.4236/jct.2012.326121 |
0.01 |
|
| 2012 |
Haraldsdottir S, Goldberg RM. Recent advances in treatment of metastatic colorectal cancer Clinical Investigation. 2: 1109-1122. DOI: 10.4155/CLI.12.116 |
0.01 |
|
| 2012 |
Sloan JA, Shi Q, Lee A, Diasio RB, Pavey ES, Sargent DJ, Goldberg RM, Sinicrope FA, Mahoney MR, Alberts SR. Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Journal of Clinical Oncology. 30: 3617-3617. DOI: 10.1200/Jco.2012.30.15_Suppl.3617 |
0.01 |
|
| 2012 |
Warren RS, Atreya CE, Niedzwiecki D, Mayer RJ, Goldberg RM, Compton CC, Weinberg VK, Bertagnolli MM. A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. Journal of Clinical Oncology. 30: 3517-3517. DOI: 10.1200/JCO.2012.30.15_SUPPL.3517 |
0.01 |
|
| 2012 |
Van Cutsem E, Grothey A, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H, Goldberg R, et al. Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update Annals of Oncology. 23: ixe10. DOI: 10.1016/s0923-7534(20)34319-2 |
0.01 |
|
| 2012 |
Sobrero A, Grothey A, Van Cutsem E, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg R, et al. O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) Annals of Oncology. 23: iv15-iv16. DOI: 10.1016/S0923-7534(19)66487-2 |
0.01 |
|
| 2012 |
Wu C, Goldberg RM. New drugs in the frontier of treatment of metastatic colorectal cancer Current Colorectal Cancer Reports. 8: 161-169. DOI: 10.1007/s11888-012-0127-4 |
0.01 |
|
| 2011 |
Sinicrope F, Foster NR, Yothers GA, Benson AB, Haller DG, Seitz J, Labianca R, Benedetti J, Goldberg RM, De Gramont A, Sargent DJ. Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21126. PMID 28022907 DOI: 10.1200/jco.2011.29.15_suppl.e21126 |
0.01 |
|
| 2011 |
Van Loon K, Wigler D, Niedzwiecki D, Hollis D, Venook AP, Blanke CD, Saltz L, Goldberg RM, Fuchs CS, Meyerhardt JA. A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14026. PMID 28022586 DOI: 10.1200/jco.2011.29.15_suppl.e14026 |
0.01 |
|
| 2011 |
Sloan JA, Mahoney MR, Sargent DJ, Hubbard JM, Liu H, Basch EM, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Alberts SR. Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6122. PMID 28022499 DOI: 10.1200/Jco.2011.29.15_Suppl.6122 |
0.01 |
|
| 2011 |
Nixon AB, Pang H, Starr M, Hollis D, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz H. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10508. PMID 28022380 DOI: 10.1200/jco.2011.29.15_suppl.10508 |
0.01 |
|
| 2011 |
Grothey A, Heun JM, Branda M, Goldberg RM, Sargent DJ. New lesions versus growth of existing disease: Does it impact prognosis? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2579. PMID 28022283 DOI: 10.1200/jco.2011.29.15_suppl.2579 |
0.01 |
|
| 2011 |
Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3607. PMID 28020864 DOI: 10.1200/Jco.2011.29.15_Suppl.3607 |
0.01 |
|
| 2011 |
Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4003. PMID 28020574 DOI: 10.1200/jco.2011.29.15_suppl.4003 |
0.01 |
|
| 2011 |
Venook AP, Niedzwiecki D, Lopatin M, Lee M, Friedman PN, Frankel W, Clark-Langone K, Yoshizawa C, Millward C, Shak S, Goldberg RM, Mahmoud NN, Schilsky RL, Bertagnolli MM. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3518. PMID 28020339 DOI: 10.1200/jco.2011.29.15_suppl.3518 |
0.01 |
|
| 2011 |
Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3522. PMID 28020320 DOI: 10.1200/Jco.2011.29.15_Suppl.3522 |
0.01 |
|
| 2011 |
Mahoney MR, Sloan JA, Hubbard JM, Liu H, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Nair SG, Sargent DJ, Alberts SR. Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3541. PMID 28020301 DOI: 10.1200/Jco.2011.29.15_Suppl.3541 |
0.01 |
|
| 2011 |
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3571. PMID 28020259 DOI: 10.1200/jco.2011.29.15_suppl.3571 |
0.01 |
|
| 2011 |
Davies JM, McRee AJ, Sanoff HK, Triglianos T, Keller K, Ivanova A, Bernard SA, Goldberg RM, Dees EC, O'Neil BH. Phase I study of the combination of everolimus (RAD001) with 5FU/LV in patients with refractory solid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 512. PMID 27985743 DOI: 10.1200/Jco.2011.29.4_Suppl.512 |
0.01 |
|
| 2011 |
Himelhoch S, Goldberg R, Calmes C, Medoff D, Slade E, Dixon L, Gallucci G, Rosenberg S. SCREENING FOR AND PREVALENCE OF HIV AND HEPATITIS C AMONG AN OUTPATIENT URBAN SAMPLE OF PEOPLE WITH SERIOUS MENTAL ILLNESS AND CO-OCCURRING SUBSTANCE ABUSE. Journal of Community Psychology. 39: 231-239. PMID 23543939 DOI: 10.1002/jcop.20422 |
0.01 |
|
| 2011 |
Brown CH, Medoff D, Dickerson FB, Kreyenbuhl JA, Goldberg RW, Fang L, Dixon LB. Long-term glucose control among type 2 diabetes patients with and without serious mental illness. The Journal of Nervous and Mental Disease. 199: 899-902. PMID 22048145 DOI: 10.1097/Nmd.0B013E3182349Fea |
0.01 |
|
| 2011 |
Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointestinal Cancer Research : Gcr. 4: 78-83. PMID 22043322 |
0.01 |
|
| 2011 |
Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. Journal of the National Cancer Institute. 103: 1498-506. PMID 21997132 DOI: 10.1093/jnci/djr310 |
0.01 |
|
| 2011 |
Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4199-204. PMID 21969501 DOI: 10.1200/JCO.2011.35.5867 |
0.01 |
|
| 2011 |
An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6592-9. PMID 21880789 DOI: 10.1158/1078-0432.Ccr-11-0822 |
0.01 |
|
| 2011 |
Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. Journal of the National Cancer Institute. 103: 1540-51. PMID 21849660 DOI: 10.1093/jnci/djr307 |
0.01 |
|
| 2011 |
Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clinical Colorectal Cancer. 10: 238-44. PMID 21820973 DOI: 10.1016/j.clcc.2011.06.012 |
0.01 |
|
| 2011 |
Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Seminars in Oncology. 38: 552-60. PMID 21810514 DOI: 10.1053/j.seminoncol.2011.05.009 |
0.01 |
|
| 2011 |
Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3153-62. PMID 21747089 DOI: 10.1200/JCO.2010.33.0092 |
0.01 |
|
| 2011 |
Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, ... ... Goldberg RM, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3146-52. PMID 21747085 DOI: 10.1200/JCO.2010.32.5357 |
0.01 |
|
| 2011 |
Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. The Oncologist. 16: 1061-8. PMID 21737577 DOI: 10.1634/theoncologist.2011-0011 |
0.01 |
|
| 2011 |
Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer. 117: 2620-8. PMID 21656739 DOI: 10.1002/cncr.25742 |
0.01 |
|
| 2011 |
Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2781-6. PMID 21646604 DOI: 10.1200/JCO.2010.33.5281 |
0.01 |
|
| 2011 |
Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. The Oncologist. 16: 859-67. PMID 21632455 DOI: 10.1634/theoncologist.2011-0064 |
0.01 |
|
| 2011 |
McRee AJ, Goldberg RM. Optimal management of metastatic colorectal cancer: Current status Drugs. 71: 869-884. PMID 21568364 DOI: 10.2165/11591770-000000000-00000 |
0.01 |
|
| 2011 |
Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown CH, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between Type 2 diabetes patients with and without serious mental illness. Psychiatry Research. 188: 109-14. PMID 21459458 DOI: 10.1016/J.Psychres.2011.03.013 |
0.01 |
|
| 2011 |
Dickerson F, Wohlheiter K, Medoff D, Fang L, Kreyenbuhl J, Goldberg R, Brown C, Dixon L. Predictors of quality of life in type 2 diabetes patients with schizophrenia, major mood disorder, and without mental illness. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 20: 1419-25. PMID 21424900 DOI: 10.1007/S11136-011-9888-5 |
0.01 |
|
| 2011 |
Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1599-606. PMID 21422438 DOI: 10.1200/Jco.2010.31.7255 |
0.01 |
|
| 2011 |
McRee AJ, Cowherd S, Wang AZ, Goldberg RM. Chemoradiation therapy in the management of gastrointestinal malignancies Future Oncology. 7: 409-426. PMID 21417904 DOI: 10.2217/fon.11.7 |
0.01 |
|
| 2011 |
Goldberg RM, Ryan DP. Scan? Cure? Sure! The Oncologist. 16: 254-6. PMID 21349952 DOI: 10.1634/theoncologist.2011-0014 |
0.01 |
|
| 2011 |
DiClemente CC, Delahanty JC, Kofeldt MG, Dixon L, Goldberg R, Lucksted A. Stage movement following a 5A's intervention in tobacco dependent individuals with serious mental illness (SMI). Addictive Behaviors. 36: 261-4. PMID 21146317 DOI: 10.1016/J.Addbeh.2010.11.002 |
0.01 |
|
| 2011 |
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 11-6. PMID 20940184 DOI: 10.1200/JCO.2010.30.0855 |
0.01 |
|
| 2011 |
O'Neil BH, Funkhouser WK, Calvo BF, Meyers MO, Kim HJ, Goldberg RM, Bernard SA, Caskey L, Deal AM, Wright F, Baldwin AS, Tepper JE. Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. International Journal of Radiation Oncology, Biology, Physics. 80: 705-11. PMID 20630669 DOI: 10.1016/J.Ijrobp.2010.02.063 |
0.01 |
|
| 2011 |
Goldberg RM. Which strategies will lead to progress in the management of colorectal cancer? Gastrointestinal Cancer Research : Gcr. 1: S33-6. PMID 19360145 |
0.01 |
|
| 2011 |
Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointestinal Cancer Research : Gcr. 1: S13-6. PMID 19330058 |
0.01 |
|
| 2011 |
Goldberg RM, Marshall JL, Kachnic LA, Venook AP. Section I: essentials of ensuring excellence in cancer care. Gastrointestinal Cancer Research : Gcr. 1: S1-3. PMID 19330057 |
0.01 |
|
| 2011 |
O'Neil B, Goldberg RM. On the state of the art of adjuvant chemotherapy for colon cancer. Gastrointestinal Cancer Research : Gcr. 1: 115-7. PMID 19262717 |
0.01 |
|
| 2011 |
Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointestinal Cancer Research : Gcr. 1: 146-54. PMID 19262703 |
0.01 |
|
| 2011 |
Shah U, Goldberg RM. Dealing With Discordance: Managing a Case Where the Patient Looks Better and the CT Scan Looks Worse. Gastrointestinal Cancer Research : Gcr. 2: 45-6. PMID 19259322 |
0.01 |
|
| 2011 |
Goldberg RM. As Federal Funding for Cancer is Cut, Researchers Struggle. Gastrointestinal Cancer Research : Gcr. 2: 165. PMID 19259296 |
0.01 |
|
| 2011 |
Harris F, Goldberg R, Hughes L, Tombazzi C. Single-dose Polyethylene Glycol with an Extended Dietary Restriction is a Practical Alternative for Veterans Unwilling to Undergo a Split-dose Regimen American Journal of Gastroenterology. 106: S580. DOI: 10.14309/00000434-201110002-01517 |
0.01 |
|
| 2011 |
Harris F, Goldberg R, Hughes L, Tombazzi C. Is a Split-dosed Bowel Preparation Practical for Veterans with an Extended Travel Time to the Procedure Center? American Journal of Gastroenterology. 106: S579. DOI: 10.14309/00000434-201110002-01515 |
0.01 |
|
| 2011 |
Goldberg R. Quality of Bowel Preparation in Early Morning Colonoscopy Using Split vs Single Dose Regimen American Journal of Gastroenterology. 106: S568. DOI: 10.14309/00000434-201110002-01486 |
0.01 |
|
| 2011 |
Goldberg R. Improved Quality and Tolerance Is Seen in Split Dose Bowel Preparation American Journal of Gastroenterology. 106: S568. DOI: 10.14309/00000434-201110002-01485 |
0.01 |
|
| 2011 |
Jessup JM, Gunderson LL, Greene FL, Washington MK, Compton CC, Sobin LH, Minsky B, Goldberg RM, Hamilton SR. 2010 staging system for colon and rectal carcinoma Annals of Surgical Oncology. 18: 1513-1517. DOI: 10.1245/S10434-010-1360-1 |
0.01 |
|
| 2011 |
Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee P, De Gramont A, Goldberg RM, Rothenberg ML, Andre T, Brienza S. Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: A comparative analysis between Asian and Western patients (pts). Journal of Clinical Oncology. 29: 3623-3623. DOI: 10.1200/JCO.2011.29.15_SUPPL.3623 |
0.01 |
|
| 2011 |
Harris FR, Goldberg R, Hughes L, Tombazzi CR. Clear Liquid Diet is Clearly Better Than Full Liquid Diet Prior to Outpatient Colonoscopy Gastroenterology. 140: S-417. DOI: 10.1016/S0016-5085(11)61712-5 |
0.01 |
|
| 2010 |
Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: CRA3507. PMID 27937468 DOI: 10.1200/Jco.2010.28.18_Suppl.Cra3507 |
0.01 |
|
| 2010 |
Novotny PJ, Smith DJ, Guse L, Rummans TA, Hartmann L, Alberts S, Goldberg R, Gregory D, Johnson M, Sloan JA. A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults. Cancer Management and Research. 2: 133-42. PMID 21188104 DOI: 10.2147/Cmar.S9668 |
0.01 |
|
| 2010 |
Davies JM, Goldberg RM. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases. Journal of Surgical Oncology. 102: 946-54. PMID 21165997 DOI: 10.1002/jso.21653 |
0.01 |
|
| 2010 |
O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). The Oncologist. 15: 1310-9. PMID 21148613 DOI: 10.1634/theoncologist.2010-0152 |
0.01 |
|
| 2010 |
Casagrande SS, Jerome GJ, Dalcin AT, Dickerson FB, Anderson CA, Appel LJ, Charleston J, Crum RM, Young DR, Guallar E, Frick KD, Goldberg RW, Oefinger M, Finkelstein J, Gennusa JV, et al. Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: The ACHIEVE trial Bmc Psychiatry. 10. PMID 21144025 DOI: 10.1186/1471-244X-10-108 |
0.01 |
|
| 2010 |
Nossel IR, Calmes CA, Brown CH, Kreyenbuhl J, Goldberg RW, Fang L, Dixon LB. Patterns of emergency department use for medical conditions among persons with serious mental illness. Psychiatric Services (Washington, D.C.). 61: 1251-4. PMID 21123411 DOI: 10.1176/Ps.2010.61.12.1251 |
0.01 |
|
| 2010 |
Goldberg RM, Bertagnolli MM. VICTOR spoiled? Journal of Clinical Oncology. 28: 4546-4548. PMID 20837951 DOI: 10.1200/JCO.2010.31.6653 |
0.01 |
|
| 2010 |
Rosenberg SD, Goldberg RW, Dixon LB, Wolford GL, Slade EP, Himelhoch S, Gallucci G, Potts W, Tapscott S, Welsh CJ. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatric Services (Washington, D.C.). 61: 885-91. PMID 20810586 DOI: 10.1176/ps.2010.61.9.885 |
0.01 |
|
| 2010 |
Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4354-63. PMID 20805450 DOI: 10.1200/JCO.2010.28.0362 |
0.01 |
|
| 2010 |
Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics Transactions of the American Clinical and Climatological Association. 121. PMID 20697547 |
0.01 |
|
| 2010 |
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3617-22. PMID 20606091 DOI: 10.1200/JCO.2010.28.1386 |
0.01 |
|
| 2010 |
McCabe MS, Wood WA, Goldberg RM. When the family requests withholding the diagnosis: who owns the truth? Journal of Oncology Practice / American Society of Clinical Oncology. 6: 94-6. PMID 20592784 DOI: 10.1200/JOP.091086 |
0.01 |
|
| 2010 |
McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3227-33. PMID 20530282 DOI: 10.1200/Jco.2009.21.7943 |
0.01 |
|
| 2010 |
Raftery L, Goldberg RM. Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer Journal (Sudbury, Mass.). 16: 214-9. PMID 20526099 DOI: 10.1097/PPO.0b013e3181ddc5ac |
0.01 |
|
| 2010 |
Goldberg RM. Strategic options on behalf of patients with metastatic colorectal cancer: Mass tumor murder versus serial tumor killing Onkologie. 33: 291-292. PMID 20523091 DOI: 10.1159/000313683 |
0.01 |
|
| 2010 |
O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clinical Colorectal Cancer. 9: 119-25. PMID 20378507 DOI: 10.3816/Ccc.2010.N.017 |
0.01 |
|
| 2010 |
Sanoff HK, Goldberg RM, Pignone MP. Assessing the quality of initial consultations regarding adjuvant colon cancer therapy. Clinical Colorectal Cancer. 9: 113-8. PMID 20378506 DOI: 10.3816/Ccc.2010.N.016 |
0.01 |
|
| 2010 |
Goldberg RW, Resnick SG. US Department of Veterans Affairs (VA) efforts to promote psychosocial rehabilitation and recovery. Psychiatric Rehabilitation Journal. 33: 255-8. PMID 20374981 DOI: 10.2975/33.4.2010.255.258 |
0.01 |
|
| 2010 |
Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials Journal of Clinical Oncology. 28: 1936-1941. PMID 20212253 DOI: 10.1200/JCO.2009.25.5489 |
0.01 |
|
| 2010 |
Brown C, Leith J, Dickerson F, Medoff D, Kreyenbuhl J, Fang L, Goldberg R, Potts W, Dixon L. Predictors of mortality in patients with serious mental illness and co-occurring type 2 diabetes Psychiatry Research-Neuroimaging. 177: 250-254. PMID 20163874 DOI: 10.1016/J.Psychres.2010.01.004 |
0.01 |
|
| 2010 |
McCleary NJ, Niedzwiecki D, Hollis D, Saltz LB, Schaefer P, Whittom R, Hantel A, Benson A, Goldberg R, Meyerhardt JA. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer. 116: 957-66. PMID 20052723 DOI: 10.1002/cncr.24866 |
0.01 |
|
| 2010 |
Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, et al. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics. 11: 13-21. PMID 20017668 DOI: 10.2217/Pgs.09.167 |
0.01 |
|
| 2010 |
de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 460-5. PMID 20008641 DOI: 10.1200/JCO.2009.23.1407 |
0.01 |
|
| 2010 |
Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin. 36: 48-70. PMID 19955389 DOI: 10.1093/Schbul/Sbp115 |
0.01 |
|
| 2010 |
Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, André T. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 754-8. PMID 19887466 DOI: 10.1093/annonc/mdp509 |
0.01 |
|
| 2010 |
Dixon LB, Medoff D, Goldberg R, Lucksted A, Kreyenbuhl J, DiClemente C, Potts W, Leith J, Brown C, Adams C, Afful J. Is implementation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? The American Journal On Addictions. 18: 386-92. PMID 19874158 DOI: 10.3109/10550490903077747 |
0.01 |
|
| 2010 |
Goldberg RJ, Burock J, Harrington CJ. Quality indicators in consultation-liaison psychiatry. Psychosomatics. 50: 550. PMID 19855045 DOI: 10.1176/appi.psy.50.5.550 |
0.01 |
|
| 2010 |
McCabe MS, Wood WA, Goldberg RM. When the family requests withholding the diagnosis: Who owns the truth? Journal of Oncology Practice. 6: 94-96. DOI: 10.1200/JOP.091086 |
0.01 |
|
| 2010 |
Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ, Goldberg RM. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Journal of Clinical Oncology. 28: 4006-4006. DOI: 10.1200/JCO.2010.28.15_SUPPL.4006 |
0.01 |
|
| 2010 |
Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee P, De Gramont A, Goldberg RM, Rothenberg ML, Andre T, Brienza S. Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients. Journal of Clinical Oncology. 28: 3611-3611. DOI: 10.1200/JCO.2010.28.15_SUPPL.3611 |
0.01 |
|
| 2010 |
Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, Gill S, Kahlenberg MS, Nair S, Alberts SR. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. Journal of Clinical Oncology. 28: 3508-3508. DOI: 10.1200/Jco.2010.28.15_Suppl.3508 |
0.01 |
|
| 2010 |
Raftery L, Bernard SA, Goldberg RM. Management of the gastrointestinal side effects of therapy in older adults with cancer Practical Geriatric Oncology. 400-418. DOI: 10.1017/CBO9780511763182.029 |
0.01 |
|
| 2010 |
Mohile SG, Kaur HP, Goldberg RM. Management of colon and rectal cancer in older adults Practical Geriatric Oncology. 148-170. DOI: 10.1017/CBO9780511763182.011 |
0.01 |
|
| 2009 |
Meyerhardt JA, Jackson McCleary N, Niedzwiecki D, Hollis D, Venook A, Mayer R, Goldberg R. Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4038. PMID 27961542 DOI: 10.1200/jco.2009.27.15_suppl.4038 |
0.01 |
|
| 2009 |
Bertagnolli MM, Niedzwiecki D, Hall M, Jewell SD, Mayer RJ, Goldberg RM, Colacchio TA, Warren RS, Redston M. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4012. PMID 27961506 DOI: 10.1200/jco.2009.27.15_suppl.4012 |
0.01 |
|
| 2009 |
Goldberg RM, Meropol NJ, Tabernero J. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointestinal Cancer Research : Gcr. 3: S23-7. PMID 20011561 |
0.01 |
|
| 2009 |
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7322-9. PMID 19934290 DOI: 10.1158/1078-0432.CCR-09-1570 |
0.01 |
|
| 2009 |
Goldberg R, Thomas H, Penner L. Issues of concern to emergency physicians in pre-retirement years: a survey. The Journal of Emergency Medicine. 40: 706-13. PMID 19926431 DOI: 10.1016/j.jemermed.2009.08.020 |
0.01 |
|
| 2009 |
Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5506-12. PMID 19858396 DOI: 10.1200/JCO.2009.22.1309 |
0.01 |
|
| 2009 |
Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG study N9741: Leveraging learning from an NCI cooperative group phase III trial Oncologist. 14: 970-978. PMID 19828593 DOI: 10.1634/Theoncologist.2009-0175 |
0.01 |
|
| 2009 |
Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clinical Colorectal Cancer. 8: 88-93. PMID 19739269 |
0.01 |
|
| 2009 |
Goldberg RM, O'Neil BH. Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs? Nature Reviews Gastroenterology and Hepatology. 6: 507-509. PMID 19713983 DOI: 10.1038/nrgastro.2009.140 |
0.01 |
|
| 2009 |
Dickerson FB, Kreyenbuhl J, Goldberg RW, Fang L, Medoff D, Brown CH, Dixon L. A 5-year follow-up of diabetes knowledge in persons with serious mental illness and type 2 diabetes. The Journal of Clinical Psychiatry. 70: 1057-8. PMID 19653985 DOI: 10.4088/Jcp.08L04602 |
0.01 |
|
| 2009 |
Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4109-15. PMID 19636001 DOI: 10.1200/Jco.2009.21.9527 |
0.01 |
|
| 2009 |
Goldberg RW, Tapscott SL, Calmes CA, Wolfe RS. HIV and hepatitis C knowledge among individuals with serious mental illness. Psychiatric Rehabilitation Journal. 33: 47-9. PMID 19592379 DOI: 10.2975/33.1.2009.47.49 |
0.01 |
|
| 2009 |
Gill S, Goldberg RM. Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC Nature Reviews Clinical Oncology. 6: 379-380. PMID 19561631 DOI: 10.1038/nrclinonc.2009.83 |
0.01 |
|
| 2009 |
Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointestinal Cancer Research : Gcr. 3: 45-8. PMID 19461906 |
0.01 |
|
| 2009 |
Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clinical Colorectal Cancer. 8: 88-93. PMID 19423501 DOI: 10.3816/CCC.2009.n.014 |
0.01 |
|
| 2009 |
Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, Sargent DJ. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3205-10. PMID 19414682 DOI: 10.1200/JCO.2008.18.3269 |
0.01 |
|
| 2009 |
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3385-90. PMID 19414665 DOI: 10.1200/JCO.2009.21.9220 |
0.01 |
|
| 2009 |
Goldberg RJ. Will psychiatry survive in the long-term care setting? Journal of the American Geriatrics Society. 57: 730-1. PMID 19405179 DOI: 10.1111/j.1532-5415.2009.02191.x |
0.01 |
|
| 2009 |
Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW. Management of infusion reactions in clinical trials and beyond: the US and EU perspectives Oncology (Williston Park, N.Y.). 23: 18-25. PMID 19385163 |
0.01 |
|
| 2009 |
Cmelak AJ, Goldberg RM. Infusion reactions associated with monoclonal antibodies in patients with solid tumors. Introduction Oncology (Williston Park, N.Y.). 23: 5-6. PMID 19385160 |
0.01 |
|
| 2009 |
Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2848-54. PMID 19380443 DOI: 10.1200/Jco.2008.20.4552 |
0.01 |
|
| 2009 |
Dixon L, Goldberg R, Iannone V, Lucksted A, Brown C, Kreyenbuhl J, Fang L, Potts W. Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalization. Psychiatric Services. 60: 451-458. PMID 19339319 DOI: 10.1176/Ps.2009.60.4.451 |
0.01 |
|
| 2009 |
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 115: 2081-91. PMID 19309745 DOI: 10.1002/Cncr.24246 |
0.01 |
|
| 2009 |
Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2116-22. PMID 19276255 DOI: 10.1158/1078-0432.CCR-08-2674 |
0.01 |
|
| 2009 |
Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1814-21. PMID 19273709 DOI: 10.1200/JCO.2008.18.2071 |
0.01 |
|
| 2009 |
Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1948-55. PMID 19255311 DOI: 10.1200/JCO.2008.20.2879 |
0.01 |
|
| 2009 |
Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Kilbourne A, Goldberg R, Dixon L, Blow FC. Understanding associations between serious mental illness and hepatitis C virus among veterans: A national multivariate analysis Psychosomatics. 50: 30-37. PMID 19213970 DOI: 10.1176/Appi.Psy.50.1.30 |
0.01 |
|
| 2009 |
Kuhn G, Goldberg R, Compton S. Tolerance for uncertainty, burnout, and satisfaction with the career of emergency medicine. Annals of Emergency Medicine. 54: 106-113.e6. PMID 19201058 DOI: 10.1016/J.Annemergmed.2008.12.019 |
0.01 |
|
| 2009 |
Wood WA, McCabe MS, Goldberg RM. Commentary: Disclosure in oncology-to whom does the truth belong? Oncologist. 14: 77-82. PMID 19147691 DOI: 10.1634/theoncologist.2008-0158 |
0.01 |
|
| 2009 |
McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Molecular Cancer Therapeutics. 8: 10-6. PMID 19139108 DOI: 10.1158/1535-7163.Mct-08-0840 |
0.01 |
|
| 2009 |
Himelhoch S, Leith J, Goldberg R, Kreyenbuhl J, Medoff D, Dixon L. Care and Management of Cardiovascular Risk Factors among Individuals with Schizophrenia and Type 2 Diabetes Who Smoke General Hospital Psychiatry. 31: 30-32. PMID 19134507 DOI: 10.1016/J.Genhosppsych.2008.07.007 |
0.01 |
|
| 2009 |
Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 872-7. PMID 19124803 DOI: 10.1200/JCO.2008.19.5362 |
0.01 |
|
| 2009 |
O'Neil BH, Goldberg RM. What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases? Nature Clinical Practice Oncology. 6: 14-16. PMID 19002130 DOI: 10.1038/ncponc1274 |
0.01 |
|
| 2009 |
Shah U, Goldberg RM. Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer. Clinical Colorectal Cancer. 7: 315-20. PMID 18794063 DOI: 10.3816/CCC.2008.n.041 |
0.01 |
|
| 2009 |
Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A Phase II Prospective Multi-Institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903 Annals of Surgical Oncology. 16: 2381-2381. DOI: 10.1245/s10434-009-0466-9 |
0.01 |
|
| 2009 |
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer Diseases of the Colon & Rectum. 52: 1679-1680. DOI: 10.1007/Dcr.0B013E3181B1D593 |
0.01 |
|
| 2008 |
Ocean AJ, Niedzwiecki D, Atkins JN, Parker B, O'Neil BH, Lee JW, Wadler S, Goldberg RM. LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4109. PMID 27951078 DOI: 10.1200/jco.2008.26.15_suppl.4109 |
0.01 |
|
| 2008 |
McLeod HL, Owzar K, Kroetz D, Innocenti F, Das S, Friedman P, Giacomini K, Goldberg RM, Venook AP, Ratain MJ. Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3513. PMID 27949752 DOI: 10.1200/Jco.2008.26.15_Suppl.3513 |
0.01 |
|
| 2008 |
Goldberg RM, Carrato A. Accomplishments in 2007 in the treatment of advanced colorectal cancer. Gastrointestinal Cancer Research : Gcr. 2: S19-24. PMID 19352463 |
0.01 |
|
| 2008 |
Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park, N.Y.). 22: 1470-9. PMID 19133603 |
0.01 |
|
| 2008 |
Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8263-9. PMID 19073970 DOI: 10.1158/1078-0432.Ccr-08-0480 |
0.01 |
|
| 2008 |
Raftery L, Sanoff HK, Goldberg R. Colon cancer in older adults. Seminars in Oncology. 35: 561-8. PMID 19027460 DOI: 10.1053/j.seminoncol.2008.08.004 |
0.01 |
|
| 2008 |
Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5721-7. PMID 19001325 DOI: 10.1200/JCO.2008.17.7147 |
0.01 |
|
| 2008 |
O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: An update of recent clinical trials Oncologist. 13: 1074-1083. PMID 18922828 DOI: 10.1634/theoncologist.2008-0083 |
0.01 |
|
| 2008 |
Drapalski AL, Milford J, Goldberg RW, Brown CH, Dixon LB. Perceived barriers to medical care and mental health care among veterans with serious mental illness. Psychiatric Services (Washington, D.C.). 59: 921-4. PMID 18678691 DOI: 10.1176/Ps.2008.59.8.921 |
0.01 |
|
| 2008 |
Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. Jama. 299: 2515-23. PMID 18523220 DOI: 10.1001/jama.299.21.2515 |
0.01 |
|
| 2008 |
French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer Clinical Cancer Research. 14: 3408-3415. PMID 18519771 DOI: 10.1158/1078-0432.CCR-07-1489 |
0.01 |
|
| 2008 |
Meropol NJ, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3229-34. PMID 18490648 DOI: 10.1200/JCO.2008.16.2339 |
0.01 |
|
| 2008 |
O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2336-41. PMID 18467725 DOI: 10.1200/JCO.2007.15.8261 |
0.01 |
|
| Hide low-probability matches. |